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ABSTRACT 
 
SUMO modification of proteins plays an important role in many cellular processes such as DNA 
replication, DNA repair, stress response, transcriptional regulation, signal transduction, cell cycle 
regulation, differentiation and cell death. SUMO modification can have varied effects on its 
substrates; it may alter subcellular localization, interaction partners or activity of the target 
proteins. SUMO modifies its substrates by forming an isopeptide bond between its own C-
terminal glycine and the ε-amino group of a preferred lysine on the target protein. The 
modification requires three enzymes, a SUMO activating enzyme E1, a SUMO conjugating 
enzyme E2, and a SUMO E3 ligase, acting in a cascade. Since all eukaryotes have only one of 
each of the first two enzymes involved in SUMOylation, the variability in substrate selection and 
the choice of SUMO paralog is often attributed to a relatively small group of the third enzymes 
in the SUMOylation pathway, collectively called the SUMO E3 ligases. SUMO modification is 
also reversible and SUMO can be cleaved off of its substrates by deSUMOylating enzymes. We 
hypothesized that the variability in SUMOylation substrate selection is guided by the choice of 
SUMO E3 ligase and each of the five different PIAS isoforms regulates distinct cellular 
pathways, including response to DNA damage, by SUMOylation of a unique subset of 
substrates. To verify our hypothesis, we ectopically expressed PIAS E3 ligases in cells and 
provided various stress stimuli, such as UV irradiation. We then analyzed the response dictated 
by the expression of each of the PIAS isoforms. We observed that both the ectopic expression of 
PIAS1 as well as the RNAi-mediated depletion of PIAS1 in cells leads to increased sensitivity of 
cells to UV irradiation and cell death. This hypersensitivity to UV irradiation is unique to PIAS1 
overexpression and is not observed with overexpression of other PIAS isoforms. Each PIAS 
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isoform shows distinct localization in cells and a unique SUMOylation profile. Our results 
indicate that PIAS1 induced cell death depends on the unique set of proteins it SUMOylates. 
Domain analysis of PIAS1 implicated the N-terminal SAP domain of PIAS1 in guiding its 
unique subcellular localization and the determination of substrate specificity. We identified 
proapoptotic protein Daxx as a mediator of PIAS1 induced apoptosis. Daxx colocalizes with 
PIAS1 modified SUMO foci in cells and RNAi-mediated depletion of Daxx alleviates UV-
induced apoptosis in PIAS1-expresing cells. Daxx is a known transcription co-repressor and 
mediates its transcription repression activity by interacting with SUMOylated transcription 
factors, including those required for production of anti-apoptotic proteins. Daxx has two motifs, 
one at its N-terminus and another at the very C-terminus, called SUMO interacting motifs (SIM), 
that are known to be important for interaction with SUMOylated proteins. Daxx is proposed to 
interact with only a subset of SUMOylated proteins; however the basis for this specificity is not 
clear. Our data suggests that the Daxx C-terminus SIM is essential for interaction with PIAS1-
mediated SUMO foci and the resulting cell death. Since cell death is regulated by a fine balance 
between the levels of pro- and anti-apoptotic proteins in cells, we analyzed the expression of the 
apoptosis mediators in cells expressing PIAS1. Results from multigene apoptotic reverse-
transcription PCR arrays have revealed that the expression of a number of pro- and anti-apoptotic 
genes is altered in PIAS1-expressing cells. Most of these proteins appear to be targets of the 
NFκB family of transcription factors. We also observed a direct interaction of the NFκB 
transcription factor protein RelB with both PIAS1 and Daxx.  
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CHAPTER 1 
An Introduction to SUMO modification 
(SMALL UBIQUITIN-LIKE MODIFIER) 
 
Post-translational modifications allow rapid and transient changes in protein localization, 
stability, interactions or activity in response to various stimuli. Most modifications involve 
attachment of small chemical groups to specific residues in the protein. Some of the well 
characterized modifications include phosphorylation, methylation, acetylation, glycosylation, 
ADP-ribosylation and prenylation. A unique class of modification discovered in the past quarter 
century involves covalent attachment of small proteins of approximately 100 amino acids to the 
ε-amino group of the lysine on cellular proteins. These modifiers belong to the Ubiquitin family 
of proteins and include Ubiquitin, Small Ubiquitin-like Modifier (SUMO), Nedd8 and Interferon 
Stimulated Gene-15 (ISG-15). Ubiquitin, the founding member of this family, was first identified 
in 1975 as a ubiquitously expressed protein in eukaryotes (1). Initial work showed that 
modification by Ubiquitin targeted proteins to proteasomal degradation. Subsequent research 
showed other regulatory functions of Ubiquitin. Elucidation of the function of Ubiquitin and the 
modification pathway earned the researchers the Nobel Prize in Chemistry in 2004 (2). The focus 
of this chapter, however, is the SUMO protein; its discovery, the modification pathway and the 
functional implications of protein modification with SUMO is extensively reviewed in the 
following pages. 
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Discovery of SUMO 
SUMO was identified by at least six different groups within a few months of each other in 1995-
97. Meluh and Koshland (3) first cloned the Saccharomyces cerevisae SUMO gene in a screen 
for suppressors of temperature sensitive mutations of the MIF2 gene, a homolog of the human 
CENP-C centromeric protein. They named this gene SMT3 (suppressor of MIF-two protein 3). 
Mannen et. al. (4) discovered its homolog HSMT3 as a ubiquitously expressed cDNA in human 
tissues. HSMT3 and yeast SMT3 were found to share 51.1% sequence identity. Three groups 
independently identified SUMO-1 in yeast two-hybrid screens. Shen et. al.(5) identified a 
homolog of yeast SMT3 in humans as an interactor of the double-stranded break repair proteins. 
Since they found this protein to be a distant homolog of Ubiquitin, they named the protein Ubl-1 
(Ubiquitin-like 1). Boddy et. al. (6) identified the same protein using PML as a bait and named it 
PIC-1 (PML interacting protein-1). They further showed that PML and PIC-1 colocalize in PODs 
(PML Oncogenic Domains).  Okura et. al. (7) identified SUMO-1 as an interactor of the death 
domain of the Fas receptor and named it Sentrin based on its apparent protective function against 
cell-death signaling.  Finally, two groups identified SUMO-1 as a protein that covalently 
modifies GTPase-activating protein RanGAP1. While Matunis and Blobel (8) called this protein 
GMP1 (for GAP-modifying protein 1), Mahajan et al. (9) came up with its present universally-
accepted moniker SUMO-1 (Small Ubiquitin-like Modifier 1).  
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Figure 1.1. Comparison between SUMO-1 and Ubiquitin structures. Despite a sequence identity of only 18%, 
SUMO and Ubiquitin share the same structural fold. Figure modified and adapted from Gill G (10). 
 
Ubiquitin and SUMO share only 18% sequence identity, but have the same ββαββαβ fold 
that has been termed the Ubiquitin fold and is shared by all Ubiquitin-like proteins. Despite a 
similarity in the tertiary structure, the charge distribution on Ubiquitin and SUMO is very 
different. SUMO also has an N-terminal extension that is not present in Ubiquitin. Also, 
although Ubiquitin and SUMO modification pathways are similar, they do not share the same 
enzymes. SUMO and Ubiquitin can modify the same sites on proteins, but the functional 
outcome in each case is different and sometimes antagonistic. 
Homologs of SUMO have been identified in most eukaryotic life forms. Invertebrates 
have a single SUMO protein, whereas mammals have been shown to have four SUMO isoforms. 
SUMO-1, SUMO-2 and SUMO-3 share nearly 50% sequence identity with the yeast Smt3 
protein. SUMO-1 is approximately 46% identical to SUMO-2 and SUMO-3. SUMO-2 and 
SUMO-3 are 96% identical, with a difference of only 3 amino acids in the N-terminus of the 
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proteins and are often thought to have the same functions in cells. Table 1 compares the 
sequence identity between the three SUMO isoforms and the yeast homolog Smt3p. Since there 
are no antibodies to differentiate between SUMO-2 and -3, they are often grouped together and 
referred to as SUMO-2/3. SUMO-1, -2 and -3 are ubiquitously expressed whereas SUMO-4 (11) 
shows limited expression in a few tissue types such as kidney, spleen and lymph nodes, and it is 
uncertain if it covalently attaches to any protein. Most of the research in the SUMO field is 
limited to the study of SUMO-1 and SUMO-2/3 isoforms. There are significant differences 
between the activity of SUMO-1 and SUMO-2/3 in cells. SUMOylated substrates often show 
SUMO isoform specificity in vivo. For example, RanGAP-1 is modified mainly by SUMO-1 
(12), whereas Topoisomerase IIα is a target of SUMO-2/3 modification (13). SUMO-1 also 
shows different localization from SUMO-2/3. SUMO-2/3 form distinct foci in the nucleoplasm 
of the interphase nuclei, whereas SUMO-1 can be seen in the nucleoli, the nuclear membrane, 
and also the cytoplasm of interphase cells (14). Also, concentrations of total and unconjugated 
SUMO-2/3 is higher than that of SUMO-1 in cells (12). Additionally, cells respond to many 
stress stimuli, such as heat shock, oxidative stress and osmotic stress, by upregulating SUMO-2/3 
modification of proteins (12). Another major difference between SUMO-1 and SUMO-2/3 is that 
SUMO-2/3 can form chains on its substrate via Lys-11 that is part of a SUMO-modification 
consensus motif (explained later in this chapter) (15).  
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Table 1.1. Comparison of sequence identity between the three SUMO isoforms from humans and the yeast 
homolog Smt3p. 
 
 Smt3p SUMO-1 SUMO-2 SUMO-3 
SUMO-1 48% ----- ----- ----- 
SUMO-2 44% 45% ----- ----- 
SUMO-3 49% 50% 96% ----- 
SUMO-4 40% 44% 85% 82% 
 
The SUMO pathway enzymes 
The SUMO conjugation pathway is very similar to the ubiquitination pathway and requires the 
sequential activity of three enzymes; a SUMO activating enzyme, which is a heterodimer of 
Aos1 and Uba2, a SUMO conjugating enzyme called Ubc9, and a SUMO ligase. In addition, 
SUMO modification requires SUMO proteases, called SENPs, which are required for both de 
novo generation of conjugation competent SUMO proteins from precursors and for regeneration 
of free SUMO by cleaving the isopeptide bond between SUMO and the substrate protein. Below 
is a summary of the discovery of these enzymes followed by the description of the SUMOylation 
pathway. 
The SUMO activating enzyme 
Similar to the Ubiquitin conjugation pathway, SUMO conjugation to other proteins involves 
three enzymes acting in a cascade. The SUMO activating enzyme E1 is a heterodimer of Aos1 
(SAE2) and Uba2 (SAE1) (16). Uba2 was first identified as a protein similar to the C-terminal 
domain of the yeast Ubiquitin activating enzyme Uba1p. UBA2 was found to be an essential 
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gene and Uba2p localized mainly to the nucleus and could not be complemented by Uba1p. 
Johnson et. al. identified Uba2p as the yeast Smt3p activating enzyme and also identified the 
protein Aos1p as the essential Uba2p binding partner required for its activity. Aos1p is similar to 
the N-terminus of the Ubiquitin E1 Uba1p enzyme. Although Aos1 and Uba2 function together 
in the SUMOylation reaction, the expression level for the two subunits is different. Uba2 protein 
levels do not change substantially through the cell cycle; Aos1 protein levels, on the other hand, 
increase substantially during the S-phase of the cell cycle (17). 
The SUMO conjugating enzyme 
Ubc9 is the only known SUMO conjugating enzyme. Ubc9 was discovered in yeast 
Saccharomyces cerevisae before the discovery of SUMO itself and was initially thought to be 
one of the Ubiquitin conjugating enzymes (UBCs). Ubc9 was found to be essential for yeast 
viability and a temperature sensitive Ubc9-1 mutant was found to arrest at G2/M phase at 37˚C 
(18). The authors further showed the stabilization of the B-type cyclins CLB5 and CLB2 in the 
Ubc9-1 strain and concluded that Ubc9 was required for Ubiquitin-mediated proteasomal 
turnover of these cyclins (18). At about the same time as Ubc9 was discovered in Saccharomyces 
cerevisae, its homolog in the fission yeast was discovered in a screen for checkpoint control 
mutants. The homolog was named Hus5 (hydroxyurea sensitive) based on the sensitivity to 
hydroxyurea (a DNA synthesis inhibitor) in strains harboring mutations in this gene. Hus5 
deletion mutants were almost inviable and the temperature sensitive alleles showed G2 arrest on 
HU or ionizing radiation treatment when coupled with other checkpoint mutations. Hus5 was 
also proposed to be a Ubiquitin conjugating enzyme based on sequence similarity, although no 
targets were identified.  
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By 1997, SUMO was well characterized as a distinct member of the Ubiquitin family. 
Johnson and Blobel (19) were the first to identify Ubc9p as the second enzyme involved in the 
SUMO-modification pathway. They showed that the yeast Ubc9p formed thioester bond with 
Smt3p, but not with Ubiquitin and that Ubc9p was the only Smt3p conjugating enzyme in yeast. 
Saitoh et al. (20) then showed that Ubc9 is required for SUMO-1 modification of RanGAP1 and 
RanBP2 in Xenopus egg extracts and that Ubc9 forms a thioester bond only with SUMO-1, and 
not Ubiquitin, confirming the earlier observation by Johnson and Blobel.   
A number of Ubc9-interacting proteins were identified in yeast-two-hybrid screens 
including c-Jun and the glucocorticoid receptor, Rad51, a number of yeast centromeric proteins, 
and Rad52, Ubl1 and p53 (21, 22). Subsequently, Saitoh et al. (23) showed that RanBP2 
associates with Ubc9 and a modified form of RanGAP1 (later identified as the SUMO-modified 
RanGAP1). Ubc9 was also shown to interact with Parp1 and Fas receptor. Tashiro et al. (24) 
showed that Ubc9 was essential for IκBα degradation, once again implicating it in the Ubiquitin-
mediated protein degradation pathway. Hahn et al. were the first to report a role for Ubc9 in a 
regulatory pathway not leading to protein degradation (25). They showed that co-expression of 
Ubc9 with the transcriptional factor ETS-1 substantially increased its transcriptional activity but 
did not affect protein stability. They speculated that the modulation of ETS-1 activity by Ubc9 
does not involve ubiquitination and ETS-1 stabilization. 
To date Ubc9 remains the only known SUMO conjugating enzyme. In human cells, a 
single Ubc9 gene has been mapped to chromosome 16p13.3. Mouse cells have one Ubc9 gene 
and three pseudogenes, of which two have an open reading frame but show differences in key 
residues and fail to rescue Ubc9 temperature sensitive phenotype in yeast. Ubc9 protein shows 
strong sequence conservation across species. Human and mouse Ubc9 are 100% identical, and 
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human Ubc9 shows 65% identity to yeast Ubc9p. Structurally, Ubc9 shows the same overall fold 
as the ubiquitin conjugating enzymes and a similar active site cleft, but there are significant 
differences in the surface charge distribution, with Ubc9 having a more positively charged non-
catalytic surface (26, 27). In fact, the positively charged surface provides the perfect binding site 
for the negatively charged surface of SUMO-1. As has been described earlier, the equivalent 
surface on Ubiquitin has an overall positive charge (28). This forms the basis for specific 
interaction of Ubc9 with SUMO-1, and not the structurally similar Ubiquitin. The binding 
interfaces between Ubc9 and SUMO-1 also display complementary hydrophobicity. 
The SUMO E3 ligases 
SUMOylation can be carried out in vitro using just the E1 and the E2 enzymes. It is known 
however, that ubiquitination requires the participation of a third class of enzymes called the 
Ubiquitin E3 ligases. The Ubiquitin E3 ligases are known to determine the substrate specificity 
in the ubiquitination pathway. The Ubiquitin ligases belong to many different families and can 
be either monomeric or multi-protein complexes. Many of the Ubiquitin ligases share a common 
Zn+ binding domain called the RING domain (RING: Really Interesting New Gene). Since 
SUMOylation draws many parallels from the ubiquitination pathway, and because it was shown 
that SUMOylation in the presence of only E1 and E2 enzymes was extremely inefficient in the 
absence of HeLa cell extracts or Xenopus egg extracts (17), the existence of an E3 SUMO ligase 
was speculated.  
In 2001, two groups independently discovered SUMO E3 ligases in yeast. 
Saccharomyeces cerevisae protein Siz1 was first characterized as a SUMO E3 ligase that is 
required for SUMO-modification of septins and was shown  to bind to both Ubc9 and yeast 
SUMO Smt3 (29). Septins are GTP binding cytoskeletal proteins required for cytokinesis in 
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yeast and are known to be SUMO modified (30, 31). Takahashi and colleagues further showed 
that the RING domain of Siz1 is required for Smt3p conjugation to the septin protein Cdc3 and 
for interaction with Ubc9 (32). They established Siz1 as a bonafide SUMO E3 ligase that acts as 
an adaptor protein between the substrate and the E2. Johnson and Gupta (33) identified Siz2, and 
the related protein Siz1, as E3 ligases in a screen for interactors of septins. They first identified 
Siz2 as one of the interactors of septins that contains a RING finger like domain and Siz1 was 
identified based on its homology to Siz2. Deletion of Siz1 and Siz2 drastically reduced 
SUMOylation in yeast and eliminated septin SUMOylation. However, unlike other SUMO 
pathway deletion mutants, deletion of Siz1 and Siz2 did not affect the viability of yeast, 
indicating that there were other SUMO ligases that carried out residual and essential 
SUMOylation in these deletion mutants (33).  
At the same time as the Siz proteins were identified as SUMO E3 ligases in yeast, the 
PIAS (Protein Inhibitor of Activated Stat) family of proteins was shown to act as SUMO E3 
ligases in mammalian cell lines (34, 35). The PIAS family of proteins was discovered in the late 
1990’s and consists of five members, PIAS1, PIASXα, PIASXβ, PIAS3 and PIASy. PIAS3 and 
PAIS1 were identified as inhibitors of Stat3 and Stat1 transcriptional activity, respectively (36, 
37), by inhibiting DNA binding by Stat proteins. PIAS1 was isolated as a SUMO-1 binding 
protein in a Yeast-two-Hybrid screen and was shown to catalyze SUMOylation of p53. PIAS1 
interacted with both Ubc9 and p53, whereas a RING domain mutant of PIAS1 could interact 
with SUMO-1 and p53, but not with Ubc9, and could not catalyze p53 SUMOylation (34). 
Sachdev and colleagues (35) identified PIASy as a SUMO E3 ligase in mammalian cells and a 
repressor of LEF1 transcription activity.  
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PIAS proteins share approximately 50% sequence identity with each other and less than 
30% sequence identity with Siz1 and Siz2. Siz and PIAS proteins however have similar domain 
architecture. All of these proteins have an N-terminal SAP domain (Scaffold attachment factor, 
Acinus and PIAS) that is involved in interaction with DNA and other proteins such as 
transcription factors; a PINIT domain that is believed to be required for subcellular localization; 
an SP-RING domain (Siz/PIAS-RING) required for E3 ligase activity; a SIM (SUMO Interacting 
Motif) for non-covalent interaction with SUMO, and finally, a variable serine/threonine rich 
region at the C-terminus (see Figure 1.2) (38). PIAS domain structure is discussed in more detail 
in chapter 3 of this dissertation. In addition to acting as adaptors in the SUMOylation pathway, 
the E3 ligases are thought to promote both SUMO paralog selection and substrate selection based 
on their localization in the cell (39, 40).  
 
 
 
Figure 1.2: Domain architecture of PIAS family of SUMO E3 ligases. The figure has been adapted and modified 
from Rytinki et al. (38). 
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The PIAS proteins have also been shown to regulate other proteins independent of the 
SUMO ligase activity. For example, PIAS1 interacts with Msx-1, regulates its DNA binding 
activity and controls its inhibitory function in myoblast differentiation (41). PIASXα-dependent 
repression of FLI-1 derives from nuclear relocalization of this transcription factor and is 
independent of its SUMOylation (42). Another example involves transcription factor Oct4, 
whose transcriptional activity is repressed by its interaction with PIASy (43). All these 
interactions involve the SAP domain of the PIAS proteins. PIASXα interacts with SUMOylated 
transcription factor Elk-1 via its SIM domain and activates Elk-1 by displacing histone 
deacetylase 2 (HDAC2) from SUMOylated Elk-1 (44). Thus, all these transcription regulatory 
functions of PIASes are dependent on the PIAS SAP or SIM domain and do not require the 
activity of the SP-RING domain (38). 
The SUMO proteases 
Like many post-translational modifications that regulate protein function, modification by 
SUMO is transient and reversible. SUMO proteases cleave SUMO off of the substrates 
(isopeptidease activity and chain editing) and are also required for maturation of SUMO by 
cleaving the C-terminal residues to reveal the diglycine motif that is used for isopeptide bond 
formation with the substrate (endopeptidase activity/ processing). Yeast has two deSUMOylating 
enzymes, Ulp1 and Ulp2 (Ubiquitin-like). Ulp2 was discovered in the screen for suppressors of 
Mif2 along with Smt3 (3). Ulp1 was identified by Li and Hochstrasser (45) in an extensive 
screen for Smt3 proteases from extracts made from bacteria transformed with groups of yeast 
proteins. Ulp1 was found to be essential for G2/S transition and mutants displayed a phenotype 
identical to Ubc9 deletion mutants (18). The following year, SUMO specific proteases, called 
SENPs (sentrin proteases), were described in mammals (46, 47).  
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 There are 6 SUMO-specific proteases in humans, SENP1, 2, 3, 5, 6 and 7. SENPs 1, 2, 3 
and 5 are closely related to yeast Ulp1, whereas SENPs 6 and 7 are similar to yeast Ulp2. Ulp1 
has both isopeptidase and endopeptidase activity, whereas Ulp2 is required for SUMO chain 
editing. Mammalian SENPs display SUMO paralog specificity and also differences in 
endopeptidase, isopeptidase, and chain editing activities (48). These differences have been 
summarized in Table 2. 
 
Table 1.2: SUMO proteases found in humans. Adapted from Mukhopadhyay and Dasso (48) and Kim 
and Baek (49). 
 
SUMO 
protease 
SUMO Paralog 
preference 
Processing Deconjugation 
Chain 
editing 
Reference
SENP1 
SUMO-1 and 
SUMO-2/3 
Yes Yes No (45, 50-52) 
SENP2 
SUMO-2/3 and 
SUMO-1 
Yes Yes No (49, 53, 54)
SENP3 SUMO-2/3 Unknown Yes No (48, 49, 55)
SENP5 SUMO-2/3 Yes Yes No (48, 49, 56)
SENP6 
SUMO-1 and 
SUMO-2/3 
No (very low) Yes (for SUMO-1) Yes (46, 48, 49)
SENP7 SUMO-2/3 No (very low) No (very low) Yes (46, 48, 49)
 
The process of SUMOylation 
SUMO-1 has a compact globular structure and the ββαββαβ fold that is characteristic of all 
Ubiquitin family of proteins, and is also found in a number of unrelated proteins across species 
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(28). In addition, SUMO has an N-terminal extension consisting of about 20 amino acid residues 
that is not present in Ubiquitin and whose function is not well characterized. SUMO proteins also 
have distinct surface charge topologies and present strongly polarized surfaces, with the negative 
and positive charges distributed to opposing faces of SUMO. This difference in surface charge 
distribution, despite the conserved protein fold, leads to different interaction specificities with the 
substrates and the modification pathway enzymes (28, 57). SUMO conjugation on the substrate 
often occurs on the ε-amino group of a lysine that is a part of the Ψ-K-x-D/E (where Ψ is a 
hydrophobic amino acid, K = lysine that is modified, x is any amino acid, followed by a 
negatively charged aspartate or glutamate residue) motif (58, 59). However, not all lysines in the 
consensus site are known to be modified in vivo, and there are a number of examples showing 
SUMOylation on lysine residues that are not a part of the consensus motif (for example; PCNA 
K164 and Topoisomerase IIα K660) (60, 61). 
All SUMO isoforms, like Ubiquitin, are expressed as precursor proteins that need to be 
appropriately processed for conjugation to substrates. SUMO proteases cleave residues from the 
C-terminus of SUMO to expose the diglycine residues in a process called maturation. The first 
step in the process of SUMO conjugation is adenylation of SUMO followed by a thioester bond 
formation between the carboxyl group of the C-terminal glycine residue of SUMO and the 
cysteine-173 of the E1 enzyme (called the SUMO activating enzyme). The mature SUMO is 
recognized by the Uba2 subunit of the Aos1/Uba2 dimer. Uba2 has three domains; the catalytic 
cystein domain that is required for the thioester bond formation with SUMO, the adenylation 
domain that contains the ATP binding site, and the Ubiquitin-fold domain (UFD) that is required 
for interaction with the SUMO E2 Ubc9 (62, 63). The Aos1 subunit participates in the 
adenylation of SUMO along with the Uba2 subunit but does not directly interact with SUMO 
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(62). In the second step of the SUMO conjugation process, SUMO is transferred from E1 to the 
E2 enzyme, forming a thioester bond with the E2 (the SUMO conjugating enzyme). The E2 
enzyme, Ubc9, is a central component of the SUMOylation machinery and interacts with all the 
proteins involved in SUMOylation. Cysteine-93 of Ubc9 is involved in the thioester bond 
formation with SUMO. In addition to covalent attachment to SUMO, Ubc9 can also interact non-
covalently with SUMO and this interaction promotes SUMO chain formation in the case of 
SUMO-2/3 (64, 65). The final transfer of SUMO to the ε-amino group of the lysine on the 
substrate protein is mediated by the E3 enzyme (the SUMO ligase). The ligases bind both Ubc9 
and the substrates and act as adaptor proteins, facilitating the interaction between the Ubc9-
SUMO conjugate and the substrate. The SP-RING domain of the ligase is required for 
interaction with Ubc9 (34) and the N-terminal SAP and PINIT domains are required for 
interaction with subtrates (63). See Figure 1.3. 
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Figure 1.3: The SUMO modification pathway. SUMOylation of proteins requires three pathway enzymes, E1, E2 
and E3. The substrate is modified at a lysine residue by formation of an isopeptide bond between ε amino group of 
lysine and the carboxyl group of the terminal glycine of SUMO. For details, see text. 
Non-covalent interaction with SUMO 
SUMO modification is known to enable interaction of its substrates with other proteins. While 
some interactions result from conformational changes in the substrate protein after SUMOylation 
that facilitate binding, other binding interactions often involve a direct association of the 
interacting protein with SUMO itself. This non-covalent interaction was shown to be mediated 
by a short hydrophobic motif found in many proteins called SUMO interacting motif or SIM 
(66). The SIM is made up of Val/Ile-Val/Ile-X-Val/Ile, flanked on either side by negatively 
charged residues or serine residues that can be phosphorylated to generate negative charges (67). 
The hydrophobic amino acids in the motif form a β-strand that can bind to the β2-strand and α-
helix of SUMO in a parallel or antiparallel orientation (68, 69). Interaction between the β-strand 
of SIM and the β2-strand of SUMO results in formation of an intermolecular β-sheet. 
Phosphorylation of serine residues near the hydrophobic core seems to favor interaction with 
SUMO-1, whereas SUMO-2 binding is unaffected by the presence or absence of negative 
charges (68). The affinity of SIM to both SUMO-1 and SUMO-2/3 is in the micromolar range 
(68) and high affinity binding between a SIM-containing protein with a SUMOylated substrate 
can result only from simultaneous interaction with both SUMO and a low affinity site on the 
substrate. This ensures specificity of binding between SIM-containing and SUMOylated proteins 
(70).   
 SUMO is known to modify many transcription factors and regulate their activity via 
interactions with repressor complexes that requires SIM domains on the repressor proteins. A 
well studied example of this is the apoptotic pathway protein Daxx. Daxx has two SIM domains, 
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one at either terminus (71, 72). Daxx is known to interact with a number of SUMOylated 
transcription factors and repress their transcription activity. Well known examples include c-Jun, 
ETS-1, NFκB and p53 (73). Daxx is described in more detail in Chapter 2. 
Physiological consequences of SUMO modification 
SUMO modification can influence the enzymatic activity of its substrate, as shown in the case of 
Topoisomerase IIα where SUMO modification at lysine 660 decreases its catenation activity (61) 
and in the case of Ubiquitin ligase BRCA-1 where SUMOylation on lysine 119 increases its 
ubiquitination activity (74). SUMO modification can also change the stability of a protein, either 
by preventing ubiquitination and subsequent degradation (as seen for IκBα, where SUMO 
competes with Ubiquitin for modification on lysine 21 (75)) or providing a new interface for 
binding of SUMO-targeted Ubiquitin ligases (StUbls) that can then lead to ubiquitination and 
degradation of the SUMOylated proteins (76). However, in most cases SUMO modification has 
been shown to regulate molecular interactions of its substrates either by creating new binding 
interfaces or by masking existing ones (70). Physiological consequences of this are quite varied. 
SUMOylation is involved in chromosome organization and function, DNA repair and 
replication, regulation of transcription, regulation of nuclear and subnuclear localization, and 
modulation of signal transduction and apoptosis (10, 77). Table 2 lists some of the proteins 
known to be SUMOylated and the consequence of their SUMOylation. This list is not 
comprehensive but is aimed at providing a good sampling of various cellular functions regulated 
by SUMO modification of various proteins. 
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Table 1.3: SUMO modification regulates multiple cellular functions. The table presents examples of 
SUMOylated proteins in various cellular pathways and a brief summary of the effect of SUMOylation. 
Cellular 
Function 
Substrate (s) Consequence of SUMOylation References 
Transcription 
Ets-1, c-Myb, AR, C-
EBP, c-Jun, p53 
Repression of transcritptional 
activation by recruitment of co-
repressors such as Daxx, histone 
deacetylases, etc. 
(78-82) 
p53 
Activation of transcriptional activity 
by preventing Mdm2 mediated 
degradation. 
(83) 
Ikaros 
Activation of transcription by 
disruption of interaction with 
repressor complexes NuRD and 
Sin3. 
(84) 
DNA Replication PCNA 
Prevents recombination at stalled 
forks during replication 
(85) 
DNA damage 
response and 
repair 
BRCA-1 
Activation of BRCA-1 ubiquitination 
activity and DNA double strand 
break foci. 
(74, 86) 
PARP-1 
Alters PARP-1 stability and affects 
other modifications on PARP-1 and 
PARP-1 activity 
(87-89) 
TIP-60 
Required for its UV-mediated 
localization to PML bodies; 
increases its acetyltransferase 
activity and p53-mediated DNA 
damage response. 
(90) 
DNA damage 
response and 
repair 
BLM helicase 
Regulates BLM’s localization and 
prevents its anti-recombinogenic 
function during homologous 
recombination repair. 
(91) 
Thymine-DNA 
glycosylase (TDG) 
TDG excises a mismatched base 
during repair but remains tightly 
bound to DNA after excision. 
SUMOylation reduces TDG’s 
affinity to the abasic site on DNA, 
allowing its release from the DNA 
and continuation of repair. 
(92, 93) 
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Cell division and 
checkpoint 
control 
Topoisomerase IIα 
Required for chromosomal 
segregation, possibly by regulating 
its DNA catenation activity at the 
centromere during anaphase 
(61) 
Aurora-B 
Regulates its autophosphorylation 
and activation 
(94) 
Signal 
Transduction 
IκBα 
Stabilization of  IκBα and inhibition 
of NFκB transcription activity 
(75) 
MAPK kinase MEK1 
In Dictostylium discoidium, MEK1 
is SUMOylated following cAMP 
stimulation and translocates to 
plasma membrane. This in turn 
translocates ERK1 to plasma 
membrane and activates it. Required 
for chemotaxis and aggregation. 
(95) 
Mdm2 
Stabilizes Mdm2 by preventing self-
ubiquitination and increases p53 
ubiquitination and degradation. 
(96) 
Nuclear 
Transport 
RanGAP 
Promotes its interaction with 
RanBP2 and localization to nuclear 
pore complex from the cytoplasm 
(8, 9) 
NEMO (IkB kinase) 
Promotes nuclear localization and 
subsequent modulation of NFkB 
activity in response to genotoxic 
stress. 
(97, 98) 
 
 
SUMOylation in development and diseases 
The importance of SUMO modification in whole organism development has been studied using 
various model organisms. Complete abrogation of SUMO modification using Ubc9 deletion 
mutants, the sole SUMO E2 conjugating enzyme, leads to cell cycle and chromosome 
segregation defects in yeast. SUMOylation regulates both the degradation of cyclinB (18) and 
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the proteolytic activity of the anaphase promoting complex/cyclosome (APC/C) (99).  In the 
Xenopus egg extract system, inhibition of SUMOylation on Topoisomerase IIα causes 
segregation defects during anaphase (13). In most multicellular organisms, loss of Ubc9 leads to 
embryonic lethality (100, 101). Figure 4 below presents a general summary of the developmental 
pathways regulated by SUMO modification. 
In addition, defects in SUMOylation have been linked to many disease states. Increased 
production of Ubc9 and SUMO E3 enzymes is seen in a number of cancers and is associated 
with poor prognosis. SUMO has been shown to regulate the activity of a number of tumor 
suppressors. A number of proteins known to be involved in neurological disorders such as 
Huntington’s, Parkinson’s and Alzheimer’s have been shown to be regulated by SUMO and in 
each of the cases, either an increase in SUMO modification or defects in SUMOylation has been 
associated with the disease state. Lamin A, which is associated with several cardiomyopathies 
and progeria, has also been shown to be SUMOylated. SUMOylation of Lamin A is important 
for its correct localization and two different diseases have been linked to reduced SUMOylation 
of Lamin A due to mutations in the SUMOylation consensus motif (102). 
A number of human pathogens also target the host SUMO pathways to establish 
infection. Viruses of the adenoviridae and herpeviridae families are known to regulate the host 
cell SUMOylation, especially in the promyelocytic leukemia nuclear bodies (PML-NBs). Viral 
proteins are also known to be targets of SUMO modification. For example, SUMOylation of 
HIV-1 integrase is important for both infectivity and replication efficiency of this virus. 
Pathogenic bacteria also target the SUMO modification pathways in the host cells. One of the 
effector proteins secreted by Yersinia species in host cells is YopJ, which is a homolog of SUMO 
proteases. Listeria monocytogenes targets Ubc9 and SUMOylated proteins for degradation (103).  
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Figure 1.4: Role of SUMO modification in mouse development. Target genes are in parentheses in orange, 
specific SUMO pathway member involved in regulation is in green. Figure adapted from Lomeli and Vasquez (104). 
 
Thus, SUMO pathway proteins have very important roles in development and 
maintenance of homeostasis. Disruptions in SUMO modifications lead to developmental 
abnormalities and promote various diseases. 
Understanding the functions of SUMO modification 
Undoubtedly, SUMO plays very important roles in all of the life processes and defects in SUMO 
modification lead to disease states. A lot of advances have been made in understanding the 
importance of this post-translational modification in the past fifteen years and many of the 
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SUMO substrates have been identified. Despite these advances, SUMO remains a difficult 
protein to study and characterizing its function in regulation of various proteins and cellular 
pathways presents many challenges. First, a very small percentage of SUMO substrates are 
actually found conjugated to SUMO at any given time in cells (77). Estimates of any given 
substrate being SUMOylated range from less than 1 percent to up to 5 percent. This variability 
makes it difficult to identify new SUMO substrates and to understand the functional significance 
of SUMO modification of a protein. Second, SUMO proteases are very active enzymes and very 
difficult to inhibit chemically. These proteases cause rapid turnover of SUMOylated proteins in 
cells and on cell lysis (77). Third, SUMO modification is highly dependent on the local 
concentration of the SUMO-pathway enzymes. For example, SUMO modification can be carried 
out efficiently in vitro even in the absence of E3 ligases if the E2 enzyme Ubc9 is used at very 
high concentrations. Not all lysines that are modified in vitro are targets of SUMO modification 
in vivo, where a more complex milieu regulates both the accessibility of the lysines available for 
modification and the localization of SUMO E3 enzyme. Fourth, mutation of individual 
SUMOylation sites on a protein can often present very subtle effects on protein function that 
might be difficult to characterize. In some cases, SUMOylation of a nearby lysine can 
sufficiently substitute for the loss of the original target lysine. Also, in the case of transcription 
regulation at least, SUMO modification does not regulate basal transcription but often 
contributes to regulation of combinatorial transcription factor binding; this effect may not be 
very apparent under normal conditions (105). Finally, whole organism knock-out studies of 
SUMO isoforms and SUMO E3 enzymes show remarkable redundancy. SUMO-1 deficient 
mouse develop normally and most of the SUMO-1 functions are efficiently substituted by 
SUMO-2/3 (106), whereas SUMO-2/3 gene silencing has more significant effects on the 
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expression of many cellular genes and on cell division rates (107). Similarly, knockout studies of 
the individual PIAS family members present very modest effects in animal models. PIASXα 
knockout mice present mild defects in testicular development and PIASy deficiency causes 
minor defects in interferon and Wnt signaling in various cell types (105). PIAS1 knockout mice 
are viable but show defects in the innate immune system development and noticeable defects in 
the regulation of NFκB and Stat1 signaling (108, 109) .  PIAS1/PIASy double knockout mice 
show early embryonic lethality (110). As a result of the difficulties presented here, SUMO 
modification is often studied using conditions wherein either SUMO itself or the modification 
enzymes are overexpressed. 
 In this thesis, I have tried to characterize the importance of SUMO E3 ligase PIAS1 in 
regulating cellular responses to genotoxic stress following UV irradiation. This project was 
initiated with the aim of understanding the importance of the PIAS family of SUMO E3 ligases 
in various cellular pathways and specifically in genome maintenance following stress. 
Overexpression of each of the PIASes leads to a distinct SUMOylation pattern in the cell. The 
PIASes also show unique localization in the nucleus. In chapter 2, we show that the 
overexpression of PIAS1 in HeLa cells, but not of any other PIAS isoforms, leads to increased 
cell death following UV irradiation. PIAS1 localization is not altered in the nucleus on UV 
irradiation and there appears to be no global changes in SUMOylation following UVR. PIAS1 
expression itself is not toxic to cells, but cells undergo rapid apoptosis after UV irradiation. 
Based on these observations, we hypothesized that overexpressed PIAS1 modifies one or more 
distinct proteins in the absence of UV irradiation. This leads to alterations in the levels of pro- 
and anti-apoptotic proteins, presumably by changes in transcription. Thus, the cells remain in a 
“sensitized” state and immediately initiate apoptosis following genotoxic stress. We identified 
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Daxx as a downstream effector protein of PIAS1-mediated apoptosis following UV irradiation. 
In chapter 3, we show that the PIAS1 N-terminal SAP domain is essential for its correct nuclear 
localization and hence for the PIAS1-mediated sensitivity to UV. We also show that Daxx itself 
is not a target of PIAS1 SUMOylation but interacts with proteins SUMOylated by PIAS1 via its 
C-terminal SIM domain. In chapter 4, we have identified NFκB transcription factor RelB as an 
interactor and potential regulatory target of PIAS1. Chapter 5 summarizes the dissertation and 
also presents future perspectives and avenues for further research in this subject. 
Our research provides new insights into the distinct roles of the PIAS family of SUMO 
ligases in regulating cellular response to genomic insult. This research will lead to a better 
understanding of how cells respond to DNA damaging stimuli and switch between a pro-survival 
and apoptotic response, of the factors involved in this decision making, and the role of 
SUMOylation in these responses. Our study has important implications in the field of DNA 
repair and apoptosis research. 
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CHAPTER 2 
The SUMO ligase PIAS1 regulates UV-induced apoptosis by recruiting Daxx 
to SUMOylated foci 
 
INTRODUCTION 
 The Small Ubiquitin-like Modifier (SUMO) proteins regulate the activity, localization 
and/or stability of various cellular proteins through a reversible covalent modification or non-
covalent interactions with their substrates (1). Three well-characterized SUMO isoforms, 
numbered 1 to 3, exist in vertebrates; SUMO-1, SUMO-2 and SUMO-3 covalently attach to a 
substrate by forming an isopeptide linkage with one or more specific lysine residues on the 
protein. In addition, SUMO-2 and SUMO-3, which share 95% sequence identity, are known to 
form poly-SUMO chains (2). SUMO modification involves the sequential transfer of a processed 
active SUMO protein from an E1 SUMO-activating enzyme to an E2 SUMO-conjugating 
enzyme and the subsequent covalent conjugation to the substrate in a reaction that involves a 
SUMO-E3 ligase. In their substrate-conjugated form, SUMO proteins can interact with other 
proteins containing a SUMO-interacting motif (SIM), which is characterized by ΨΨXΨ or 
ΨXΨΨ residues (where Ψ is a hydrophobic amino acid) and is often flanked by negatively 
charged residues (3, 4). Therefore, protein modification by SUMO can lead to new protein-
protein interaction modules.  
 There is only one SUMO E1 enzyme and only one SUMO E2. Mutations that completely 
abrogate the function of either of these two enzymes lead to a complete absence of SUMOylation 
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and are lethal. The diversity of SUMO substrates is presumably governed by a small number of 
SUMO E3 ligases that exist in cells. The PIAS family of SUMO E3 ligases contains homologs in 
both vertebrates and invertebrates, and is characterized by the presence of a zinc-binding SP-
RING domain (5, 6). In addition, PIAS family members all contain an N-terminal SAP (scaffold 
attachment factor, acinus and PIAS) domain that is involved in DNA binding and protein-protein 
interactions, a PINIT domain that has been proposed to be required for subcellular localization 
and substrate interactions (7), a SUMO-interacting motif (SIM), and a variable C-terminal 
serine-threonine-rich region. Mammals contain five major PIAS isoforms, PIAS1, PIAS2α/Xα 
and 2β/Xβ, PIAS3 and PIAS4/y. PIAS proteins are functionally similar to RING finger ubiquitin 
ligases and act as adaptor proteins that bridge the SUMO-conjugated E2 enzyme and the 
substrate in the SUMOylation reaction. The SP-RING finger domain is essential for the SUMO-
ligase activity of PIAS proteins. It has also been suggested that PIAS proteins promote SUMO 
paralog selection (6, 8).  
 Various cellular stress stimuli have been demonstrated to induce global protein 
modification by SUMO-2/3, which suggests that cells may use SUMO-modification as a 
protective response (9). A number of DNA damage repair (DDR) pathway proteins have recently 
been shown to be modified by SUMO. For example, the SUMO-conjugation of the base excision 
repair (BER) enzyme thymine DNA-glycosylase (TDG) has been shown to regulate its DNA-
binding activity (10). Similarly, NER, NHEJ and HR pathway proteins have been shown to be 
SUMOylated. PIAS1 and PIAS4 have been implicated in DNA double-strand break repair that 
depends on the SUMO-2/3 conjugation of BRCA1 and the SUMO-1 conjugation of 53BP1, 
respectively (11). PIAS proteins are also known to promote apoptosis. UV irradiation-induced 
TIP60 SUMOylation has been shown to be essential for its localization to PML bodies and the 
 
35 
 
activation of the p53-dependent transcriptional response (12). PIAS1 has been shown to initiate 
apoptosis in response to the presence of reactive oxygen species by JNK activation (13). 
 Daxx is another PML (promyelocytic leukemia protein) -associated protein that has been 
shown to participate in UV-induced cell death via the activation of the JNK pathway (14). Daxx 
is a well-characterized SUMO-interacting protein and interacts with SUMO-modified proteins 
via its N- and C-terminal SIMs (15). Daxx acts as a transcriptional co-repressor for a number of 
transcriptional factors, including ETS-1 and NF-κB, and has been shown to both activate and 
repress p53 transcriptional activity (16). Daxx may also regulate chromatin dynamics by binding 
to histone deacetylases and chromatin remodeling proteins (17). Daxx interacts with the 
SUMOylated form of the PML protein (18), and the sequestration of Daxx in PML bodies 
suppresses its transcription inhibition function (19). Various lines of evidence suggest that Daxx 
can act as both a pro- and an anti-apoptotic protein. Daxx is known to be involved in the axin-
mediated activation of p53 transcription, which leads to apoptosis (20). Daxx has been shown to 
suppress anti-apoptotic gene transcription by repressing NFκB transcriptional activity (21). 
Conversely, RNAi-induced Daxx silencing has been shown to increase apoptosis (22) and 
sensitize cells to cellular stressors, such as UV and TNF-α (23). 
 In this chapter, we present our finding that the exogenous expression of PIAS1, but not 
other members of the PIAS family of SUMO E3 ligases, increases UV-induced apoptosis in 
HeLa cells. PIAS1’s SUMO-ligase activity is essential for increased UV sensitivity and that 
increased apoptosis is mediated by the recruitment of Daxx to SUMOylated PIAS1 foci. Based 
on these results, I propose a novel, specific role for PIAS1-mediated SUMOylation in sensitizing 
cells to UV damage through Daxx. 
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RESULTS 
PIAS1-transfected cells display increased sensitivity to UV irradiation 
To understand the specific roles of the PIAS family of SUMO ligases in the DNA damage 
response, we expressed C-terminal mCherry-tagged PIAS1, PIAS2α/Xα, PIAS3 or PIAS4/y in 
HeLa cells and subjected the cells to 30 J/m2 of UV irradiation, twenty-four hours after 
transfection. Four hours post-UV irradiation, apoptotic cells were counted based on their aberrant 
nuclear morphology and fragmentation. Fixed cells were also stained with an anti-Parp1 
antibody (Fig. 1A). Parp1 is a known substrate of caspase-3 during apoptosis (24). In non-
apoptotic cells, Parp1 is present only in the nucleus, whereas in apoptosis-initiating cells, cleaved 
Parp1 can be detected in the cytoplasm. Based on nuclear morphology and Parp1 staining, we 
determined that less than 2% of the untransfected cells underwent apoptosis within four hours 
after irradiation. In cells expressing PIAS family proteins, 5-20% of each group of PIAS-
expressing cells were apoptotic in the absence of UV irradiation. Four hours after irradiation, the 
PIAS1-expressing cells contained significantly more apoptotic cells compared with the other 
PIAS-expressing cells; hereafter, we refer to this phenotype as “UV-hypersensitive apoptosis” 
(Fig. 1B). In the mock-irradiated condition, the PIAS1-expressing cells displayed better survival 
when compared with the other PIAS-expressing cells, which indicates that PIAS1 expression is 
less toxic to HeLa cells than that of other PIAS proteins (Fig. 1A). UV-hypersensitive apoptosis 
was observed in several different cell lines, suggesting that the role of PIAS1 is not specific to 
the genetic background of the HeLa cells. We calculated the apoptotic ratio by normalizing UV 
irradiation induced apoptosis to the apoptosis in mock-irradiated cells. As shown in Fig. 1C, 
PIAS1-expressing cells displayed more than twice the amount of apoptosis compared to other 
PIAS-expressing cells 4 hours after irradiation. These results suggest a specific role for PIAS1 in 
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UV-induced apoptosis. This increase in apoptosis in cells expressing PIAS1 could be suppressed 
by treating cells with caspase-3 inhibitors before and during recovery from the UV-treatment 
(Fig. 1D). 
 
 
 
Figure 2.1: PIAS1 overexpression sensitizes HeLa cells to UV irradiation. (A) Parp1 localization changes in 
apoptotic cells. Parp1 is a known substrate of activated caspase3. Uncleaved Parp1 mainly resides in the nucleus, but 
after cleavage by caspase3, the cleaved fragment can be detected in the cytoplasm as well. This change in Parp1 
localization often precedes a change in nuclear morphology. (B) PIAS1-expressing cells undergo increased UV 
irradiation-induced apoptosis. HeLa cells were UV-irradiated (30 J/m2) or mock-irradiated 24 hours after 
transfection with the PIASes. After a 4-hour recovery period, the numbers of dead and surviving cells were counted 
based on their nuclear morphologies and Parp1 staining patterns. The plotted values are the average of five 
independent experiments. The error bars represent 1 standard error of the mean. (C) The differences between UV-
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irradiation induced apoptosis in various PIAS isoform-expressing cells is emphasized by plotting the ratio of the 
percentage of apoptotic cells after UV-irradiation over the percentage of apoptotic cells in mock-irradiated samples, 
as calculated for Fig. 1B. (D) Caspase inhibitor reduces PIAS1-mediated UV-induced apoptosis. PIAS1-transfected 
cells were treated with either DMSO or 200uM caspase-3 inhibitor III (DEVD-CMK, EMD Biosciences, 
Massachusetts, USA) for 2 hours before UV irradiation and also during the four hour recovery period post-
irradiation. Apoptotic cells were counted based on nuclear morphology and Parp1 staining of fixed cells. 
 
PIAS isoforms show distinct nuclear distribution and SUMOylation profiles 
 The SUMO substrate selectivity of PIASes can stem from their distinct localizations 
within the cell (8, 25). To obtain additional insight into the substrate specificity of PIAS proteins, 
we compared the localization of each of the PIAS isoforms. All of the mCherry-tagged PIAS 
isoforms localized to the nucleus, and each of the PIAS isoforms was uniquely distributed in the 
nucleus. PIAS1 showed numerous (>30) small foci in the nucleus at low expression levels and 
comparatively fewer (<10) but larger foci at high expression levels. The foci that were formed by 
PIAS2α/Xα were more numerous (>100) and had low PIAS2α/Xα expression levels. PIAS3, 
when expressed at low levels, showed a similar localization pattern to that of PIAS1 high 
expression foci, whereas PIAS3 was homogenously distributed in the nucleus at a high 
expression level. Finally, PIAS4/y-mCherry was homogenously distributed within the nucleus, 
and a small number of faint foci were visible (Figure 2A). All of the isoforms showed varying 
levels and patterns of colocalization with the SUMO isoforms and strongly recruited SUMO to 
foci, which yielded SUMO localization patterns that are distinct from the SUMO distribution that 
was observed in untransfected cells (Figure 2A).  
Because the SUMO ligase activity of PIAS1 is required for UV-hypersensitive apoptosis, 
we examined whether all PIAS proteins have similar SUMO ligase activity in transfected cells. 
To compare the SUMOylation profiles of the PIAS proteins, we enriched PIAS-expressing cells 
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based on the mCherry signal using a cell sorter (MoFlo XDP, Beckman-Coulter) from both 
mock-irradiated and UV-irradiated samples. The SUMOylation profile of the sorted cells was 
analyzed by immunoblotting with either anti-SUMO-1 or anti-SUMO-2/3 antibodies (Fig. 2B), 
and anti--actin was used as a loading control. All of the PIAS isoforms increase the levels of 
SUMO-1 modification on several proteins that range in molecular weight from 95 kD to 300 kD. 
However, no significant difference was observed in the pattern of SUMO-1-modified proteins 
between the cells that expressed PIAS1 and those that expressed other PIASes, suggesting that 
SUMO-1 modification may not be relevant to UV-hypersensitive apoptosis. Conversely, the 
SUMO-2/3 immunoblot shows clear differences in the SUMOylation profile upon the expression 
of various PIAS proteins. Each of the PIAS proteins produce a number of unique SUMO-2/3 
modified bands, indicating that each PIAS protein has a unique subset of substrates for SUMO-
2/3 modification. The molecular weights of most of the unique bands are greater than 130 kD. 
PIAS2α/Xα appears to give the most intense SUMOylation signals, although it does not show 
UV-hypersensitive apoptosis. This suggests that increasing SUMOylation in cells alone does not 
contribute to UV-hypersensitivity. We did not observe any significant differences in the 
SUMOylation pattern between the mock- and UV-irradiated cells in any of the samples. In 
general, HeLa cells seem to slightly repress SUMOylation in response to UV irradiation. These 
results indicate that all PIAS proteins promote SUMOylation of their SUMO-2/3-specific 
substrates in cells, and PIAS1-specific substrates may contribute to the sensitization of cells to 
UV irradiation and apoptosis induction. 
 
. 
 
40 
 
 
 
 
41 
 
Figure 2.2: PIAS family SUMO ligases show distinct localization and SUMOylation substrates in cells. (A) 
Differential localization of PIAS family of SUMO ligases in HeLa cells. PIAS1, PIASXα, PIAS3 and PIASy C-
terminal mCherry fusion constructs were transfected into HeLa cells. Cells were immunostained with anti-SUMO1 
and anti-SUMO2/3 antibodies 24 hours after transfection. (B) PIAS family of SUMO ligases have distinct substrates 
in cells. HeLa cells overexpressing mCherry fusion PIASes were sorted from untransfected cells and SUMOylation 
in transfected cells analyzed using either anti-SUMO1 or anti-SUMO2/3 antibody after western blot. Some of the 
unique SUMOylated bands have been marked with an asterisk 
PIAS1’s SUMO ligase activity is required for UV-sensitivity 
PIAS family SUMO E3 ligases have been shown to regulate a number of cellular pathways 
independent of their SUMO ligase activity (6). PIASes are known to regulate the activity of other 
proteins by altering their localization via direct interactions that do not depend on the presence of 
a functional SP-RING domain. For example, PIAS1 has been shown to regulate apoptosis-related 
proteins, such as p53 and Msx1, independent of its SUMO ligase activity (26-28). To determine 
whether PIAS1’s SUMO ligase activity is required for UV-hypersensitive apoptosis, we 
expressed the PIAS1 C351S mutant and a PIAS1 N440 deletion mutant in HeLa cells and 
compared the rate of UV-hypersensitive apoptosis to that in cells expressing wild-type PIAS1 
(PIAS1wt). The C351S mutant contains a mutation in the SP-RING domain that disrupts RING 
finger formation; therefore, it lacks SUMO E3 ligase activity (29). The PIAS1 N440 deletion 
mutant lacks the C-terminal SIM domain that has been shown to increase the affinity of PIAS for 
SUMO, although it is not required for SUMOylation, in vitro (7). PIAS1wt and the two mutants 
did not show similar localization in the nucleus. PIAS1 forms numerous (>30) small foci in the 
nucleus at low expression levels and comparatively fewer (<10) but larger foci at high expression 
levels.  In contrast, the PIAS1 C351S mutant has a more homogenous nuclear distribution and 
forms very few foci (Fig. 3A). PIAS1 N440 also shows a homogenous nuclear distribution and 
does not form clear foci.  
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As we predicted, PIAS1 C351S did not increase the SUMO-2/3 modification of cellular 
proteins. Rather, it suppressed most SUMO-2/3 modifications and acted in a dominant-negative 
manner (Fig. 3B). PIAS1 N440, however, showed higher SUMOylation activity than PIAS1wt. 
Our results are in agreement with earlier studies showing that the SIM domain of yeast PIAS 
homolog Siz1 is dispensable for specific substrate recognition and site selective SUMOylation of 
PCNA (7). HeLa cells expressing PIAS1 C351S and PIAS1 N440 showed more cell death 
compared with PIAS1wt-expressing cells. Four hours after UV irradiation, the PIAS1 C351S-
expressing cells did not show elevated apoptosis levels, unlike the PIAS1wt-expressing cells 
(Fig. 3C). This result indicates that the SUMO ligase activity of PIAS1 is required for UV-
hypersensitive apoptosis, and that neither the inhibition of SUMOylation by the PIAS1 C351S 
mutant nor the aberrant SUMOylation by PIAS1 N440 contribute to UV-hypersensitive 
phenotype. 
 
 
Figure 2.3. PIAS1’s SUMOylation activity is required for UV sensitivity. (A) The ligase-dead mutant (PIAS1 
C351S) and the SIM domain truncation mutant (PIAS N440) do not exhibit nuclear punctate localization that is 
shown by wild-type PIAS1. C-terminal mCherry-tagged PIAS1wt, PIAS1 C351S or PIAS1 N440 were expressed in 
HeLa cells for 24 hours. Fixed cells were stained with anti-SUMO-1 and anti-SUMO-2/3 antibodies. The images 
were acquired using a confocal microscope using a 100X objective. Scale bar: 5 μm. (B) Altered SUMOylation 
profile in PIAS1-mutant-expressing cells. The cells expressing mCherry-tagged PIAS1 C351S and PIAS1 N440 
were sorted, and their SUMO-2/3 profile was compared with those of PIAS1-expressing cells by immunoblotting 
using the anti-SUMO-2/3 antibody. (C) Wild-type PIAS1, but neither PIAS1 C351S nor PIAS1 N440, promotes 
increased apoptosis upon UV irradiation. The plotted values are an average of three independent experiments. The 
error bars represent 1 SEM. The percentage of apoptotic cells was determined, as explained in Figure 2.1A. 
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PIAS1 colocalizes with Daxx in cells 
Because PIAS1 promotes SUMOylation of specific cellular proteins, we aimed to identify the 
protein(s) that interact with SUMOylated substrates in PIAS1-expressing cells. Daxx was one of 
the logical candidates for this approach because it is a known pro-apoptotic protein that contains 
two SUMO-interaction motifs (one at each terminus) (15). We immunostained PIAS1-
transfected, mock- or UV-treated, cells with an anti-Daxx antibody. In untransfected cells, Daxx 
showed small punctate localization in the nucleus which largely coincided with promyelocytic 
leukemia nuclear bodies (PML-NBs). Daxx localization was altered in the PIAS1-expressing 
cells. In approximately 20 to 30 percent of the PIAS1-expressing cells, Daxx colocalized with 
some of the PIAS1 foci (Figure 4A). This colocalization was more easily observed in the high-
expression PIAS1 foci in both the mock-irradiated and UV-irradiated cells. 
 Daxx is known to localize to PML-NBs in cells and this localization requires PML 
SUMOylation. The colocalization of PML and Daxx has been proposed to regulate Daxx’s co-
repressor function (19). We therefore examined whether the PML/Daxx interaction was altered 
by PIAS1 expression. By immunofluorescence staining, we observed that PIAS1 also colocalizes 
with PML, but Daxx and PML show very little colocalization in PIAS1-expressing cells. The 
colocalization of PIAS1 with PML and Daxx appears to be mutually exclusive. However, in 
PIAS1 C351S-expressing cells, PML and Daxx largely remain colocalized (Figure 4B). We 
calculated the colocalization between PML and Daxx in PIAS1wt- and PIAS1 C351S-expressing 
cells using the cell image analysis software, CellProfiler v2.0 (30). The correlation between each 
focus of PML and Daxx was calculated using Pearson’s correlation coefficient. As shown in 
Figure 4C, in PIAS1 C351S-expressing cells, over 35% of Daxx foci strongly correlate with the 
PML foci. In contrast, PIAS1wt-expressing cells display a strong correlation in less than 5% of 
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Daxx and PML foci. To further evaluate PML/Daxx interaction in each cell, we counted the 
number of cells showing a strong correlation (greater than 0.5) coefficient between PML and 
Daxx. As shown in Figure 4D, in nearly 80% of the PIAS1-expressing cells, less than 5% PML 
foci showed a strong correlation with Daxx. In contrast, nearly 40% of the C351S-expressing 
cells showed greater than 50% of the PML foci strongly colocalizing with Daxx, and almost an 
equal number of cells showed between 26-50% of the PML foci colocalizing with Daxx. This 
suggests that the inhibition of SUMOylation by PIAS1 C351S expression does not disrupt the 
PML/Daxx interaction, but increased SUMOylation by PIAS1wt promotes the dissociation of 
Daxx from PML. These observations strongly suggest that Daxx preferentially localizes to 
PIAS1-induced SUMO foci, which may then lead to UV-hypersensitive apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. PIAS1 colocalizes with Daxx in cells and regulates its localization to PML bodies. (A) Daxx 
colocalizes with the SUMOyalted foci in PIAS1-expressing cells, but not in PIAS1 C351S-expressing cells. PIAS1-
mCherry and PIAS1 C351S-mCherry fusions were expressed in HeLa cells. The cells were stained with an anti-
Daxx antibody 24 hours after transfection. The stained samples were imaged using confocal microscopy using a 
100X objective. Scale bar: 5 μm.  (B) PIAS1 expression prevents Daxx from colocalizing with PML bodies. PIAS1- 
or PIAS1 C351S-transfected cells were stained with anti-Daxx and anti-PML antibodies. Daxx colocalizes with 
PML bodies in PIAS1 C351S-expressing HeLa cells but not in PIAS1-expressing cells. Scale bar: 5 μm. PIAS1-
Daxx and PIAS1-PML colocalization is enlarged (inset). (C) Quantitative measurement of colocalization correlation 
between Daxx and PML in PIAS1 vs PIAS1 C351S expressing cells. PIAS1 or PIAS1 C351S expressing cells were 
stained with anti-Daxx and anti-PML antibodies. Over sixty images were acquired using a confocal microscope 
from three independent experiments. Pearson’s correlation between Daxx and PML was calculated in the transfected 
cells from the images using CellProfiler v2.0 software.  
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The depletion of Daxx alleviates PIAS1-induced apoptosis 
Because we observed that PIAS1-mediated SUMOylation alters the localization of Daxx, which 
is known to regulate apoptosis, we examined whether Daxx acts as a pro-apoptotic protein 
downstream of PIAS1. We utilized Daxx siRNA knockdown to elucidate the role of Daxx in 
PIAS1-mediated UV-hypersensitive apoptosis. We used two different siRNAs against Daxx and 
depleted approximately 70% of Daxx within 48 hours of treatment using either siRNA (Figure 
5A). Under these conditions, we expressed PIAS1-mCherry fusion proteins to measure UV-
hypersensitive apoptosis. In the Daxx depleted cells, PIAS1-mediated UV-hypersensitive 
apoptosis was significantly reduced. Compared with the control siRNA-treated cells, the cells 
that were treated with Daxx siRNAs showed 50% less apoptosis following UV irradiation. There 
was a slight increase in non-UV-induced apoptosis in the PIAS1-expressing cells that were 
treated with Daxx siRNAs (Figure 5B). This result indicates that Daxx plays a critical role in 
PIAS1-mediated UV-hypersensitive apoptosis and acts downstream of PIAS1-induced 
SUMOylation. 
 Taken together, these data indicate that PIAS1 has a distinct role in regulating Daxx 
activity among the PIAS family of SUMO ligases. PIAS1-specific SUMOylation alters Daxx’s 
function by recruiting Daxx to SUMOylated proteins, which allows Daxx to mediate UV-
hypersensitive apoptosis. 
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Figure 2.5. Daxx depletion alleviates UV sensitivity in PIAS1-expressing cells.  (A) Treatment with either siRNA 
reduced cellular Daxx by nearly 70%. Daxx was depleted from HeLa cells using two different siRNAs against Daxx. 
mCherry-tagged PIAS1 was transfected into HeLa cells 24 hours after the Daxx siRNA treatment. siRNA-treated 
HeLa cell extracts were immunostained with anti-Daxx antibody after Western blot. Anti-β-actin antibody was used 
as a loading control. (B) Expression of Daxx siRNA but not the control siRNA significantly reduced apoptosis in 
cells expressing PIAS1 after UV treatment. Daxx siRNA treated, PIAS1 expressing cells were UV irradiated, and 
the apoptotic cells were counted, as described above 48 hours after Daxx depletion. The plotted values are an 
average of three independent experiments. The error bars represent 1 s.e.m. 
 
DISCUSSION 
Many different stress stimuli lead to the SUMOylation of several cellular proteins that act in the 
damage repair pathway or lead to apoptosis (6, 9). Members of the PIAS family of SUMO E3 
ligases have been shown to have distinct substrates and contribute to SUMO paralog selectivity 
in response to various stress pathways (6). Various pieces of evidence indicate that PIAS1 is an 
important regulator of the cellular stress response. Galanty et al. (11) have shown that PIAS1 
stimulates double strand break repair by modifying BRCA1 with SUMO-2/3. PIAS1 has also 
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been shown to participate in cellular responses to oxidative stress by regulating the JNK pathway 
and PIAS1 knockdown prevents reactive oxygen species-induced apoptosis (31, 32). PIAS1 also 
SUMOylates p53 and leads to an increase in p53 transcriptional activity (26, 33). In this chapter, 
we described a specific role of PIAS1 in regulating apoptosis in response to UV irradiation. The 
overexpression of PIAS1 in HeLa cells leads to increased sensitivity to UV irradiation and 
results in an increase in cell death by four hours after UV irradiation. The expression of other 
members of the PIAS family does not lead to increased apoptosis after UV irradiation. PIAS1’s 
SUMO ligase activity is required for inducing hypersensitivity to UV irradiation; a ligase 
inactive mutant of PIAS1 fails to elicit UV-hypersensitivity in cells. Each of the PIASes displays 
a distinct SUMO-substrate profile and localization in the nucleus, but only PIAS1 expression 
leads to increased apoptosis following UV irradiation. This indicates that substrates unique to 
PIAS1 participate in UV-induced cell death response. The identification of PIAS isoform-
specific substrates and the mediators of specific localization of each PIAS protein will be 
essential to comprehensively understand PIAS-mediated SUMOylation in stress-related 
apoptosis. 
PIAS1-SUMOylated foci recruit the apoptotic protein Daxx. Daxx is a well-known 
apoptosis regulator that acts primarily as a transcriptional regulator, although its status as a pro- 
or anti-apoptotic factor is debated (16, 17, 34). Daxx contains two well-characterized SUMO-
interacting motifs (SIM) at its termini that allow it to interact with SUMOylated proteins in cells 
(15, 35, 36). In response to UV irradiation, Daxx appears to act as a pro-apoptotic protein 
downstream of PIAS1. We confirmed the involvement of Daxx using a knockdown approach. 
PIAS1-induced UV sensitivity is alleviated when Daxx levels are reduced using siRNAs against 
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Daxx. Overall, our data show that the SUMOylation-dependent regulation of Daxx is critical for 
sensitizing cells to UV irradiation, which is consistent with the  previously proposed model (37).  
 Daxx is known to localize to PML bodies in cells (18). The PML-NB recruitment of 
Daxx has been shown to attenuate its repressive activity toward several promoters (19). In 
PIAS1-expressing cells, Daxx does not localize to PML bodies; instead, it relocates to PIAS1 
SUMOylation foci. Because a large number of known SUMOylated proteins are transcription 
factors, and many SUMOylated transcription factors are known targets of Daxx-mediated 
transcriptional repression, PIAS1 may mediate the SUMO-2/3 modification of transcription 
factors, and Daxx may act as a co-repressor in a SUMOylation-dependent manner. Therefore, 
Daxx may suppress the production of anti-apoptotic factors, which may therefore sensitize cells 
to cellular stressors, such as UV irradiation. Daxx has been shown to repress the transcription of 
anti-apoptotic proteins downstream of NFκB (21), and it would be interesting to examine 
whether this pathway is also targeted downstream of PIAS1 during UV-hypersensitive apoptosis. 
 In conclusion, we show that PIAS1 sensitizes cells to UV stress-induced apoptosis 
through the recruitment of Daxx to PAIS1-specific SUMOylated substrates. Daxx itself does not 
appear to be a substrate of PIAS1, but interacts with SUMOylated substrates. The identification 
of the specific PIAS1 substrates, their mechanism of interaction with Daxx and Daxx’s 
downstream targets will be important to promote our understanding of PIAS1-mediated cell 
death in response to UV irradiation. 
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EXPERIMENTAL PROCEDURES 
DNA constructs and cell transfection: mCherry DNA was amplified and cloned into the 
pCDNA His maxC vector (Invitrogen, Carlsbad, CA) using NotI and XhoI restriction enzymes to 
create a pCDNA4 His maxC mCherry vector. DNA sequences encoding PIAS1, PIAS2/Xα, 
PIAS3 and PIAS4/y were amplified and subcloned into the pCDNA4 His maxC mCherry vector 
using EcoRI and NotI restriction enzymes; this produced a C-terminal mCherry fusion for the 
PIAS proteins. The PIAS1 C351S mutant was generated using a QuikChange II XL Site-
Directed Mutagenesis kit from Agilent Technologies (Santa Clara, CA).  HeLa cells were grown 
to 50% confluence in McCoy’s medium (Mediatech Inc., Manassas, VA) that was supplemented 
with 10% FBS and transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as per 
manufacturer’s instructions.  
UV irradiation and apoptotic assays: The transfected HeLa cells were either mock-irradiated 
or irradiated with 30 J/m2 of UV using an Entela UV crosslinker. In brief, the cells were washed 
twice with PBS and then irradiated in PBS. After irradiation, the PBS was removed and replaced 
with growth medium. The cells were analyzed 4 hours or 24 hours after UV irradiation. Cells 
that were grown on coverslips were fixed with 4% paraformaldehyde and permeabilized using 
0.2% Triton-X-100. The cells were then stained with an anti-Parp1 antibody and Hoechst 33342 
dye (which stains DNA) for immunofluorescence analysis. The apoptotic cells were counted 
based on DNA morphology and the re-distribution of Parp1 into the cytoplasm.  
Cell sorting and Western blot analysis: HeLa cells that were transfected with mCherry-tagged 
PIAS family members were sorted from the untransfected cells using a Beckman Coulter MoFlo 
XDP sorter  (Fort Collins, CO) with a 488 nm excitation filter and a 620/29 nm emission filter. 
The sorting was performed 4 hours after the mock or UV irradiation. The sorted cells were 
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subjected to a Western blot analysis, and the protein levels were normalized by staining for β-
actin (Cell Signaling Technology, Danvers, MA). 
Immunofluorescence analysis: Transfected and treated cells were fixed with 4% 
paraformaldehyde and permeabilized using 0.2% Triton-X-100. The cells were then blocked for 
15 min with 5% BSA and 2.5% fish gelatin prepared in PBS-T. After washing, the cells were 
stained for one hour with the appropriate antibody following the manufacturer’s dilution 
instructions, which was followed by staining with an Alexa dye-tagged secondary antibody 
(Invitrogen, Carlsbad, CA) and Hoechst 33342 dye. The cells were mounted using Vectashield 
mounting medium (Vector Laboratories, Burlingame, CA), and imaged using a DSU-10 spinning 
disk (Yokugawa-type) confocal microscope that was equipped with an Olympus 100X objective 
(with a numerical aperture of 1.45), Hamamatsu EMCCD and the Slidebook imaging package 
(Intelligent Imaging Innovations, Denver, CO). An anti-human Daxx antibody was purchased 
from Sigma and an anti-PML antibody from SantaCruz Biotechnology Inc. (Santa Cruz, CA). 
The other antibodies that were used in this study were generated in the lab. 
Daxx silencing using siRNAs: siRNAs against human Daxx were obtained from Invitrogen 
(Carlsbad, CA) (siRNA1:AUCCAAUUCUGAGAGAUCCAACUCC and  
siRNA2: AUCAGAGUCUGAGAGCACGAUGAUC). HeLa cells were transfected with each of 
the siRNAs using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) using the reverse 
transfection method. The cells were plated to obtain a next-day confluency of 50%. Twenty-four 
hours after the siRNA transfection, the cells were transfected with pCDNA4 His maxC Cherry. 
The cells were UV-irradiated 48 hours after the siRNA treatment as described above, and the 
apoptotic cells were counted 4 hours later. 
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Colocalization correlation calculations 
The colocalization correlation between PML and Daxx was calculated using 90 confocal images 
acquired from three independent experiments as described above. CellProfiler v2.0 (30) cell 
image analysis software was used to calculate colocalization using Pearson’s correlation. The 
Otsu Adaptive threshold was used to identify and select all nuclei expressing mCherry. The 
correlation was calculated between Daxx and PML spots within the selected nuclei.  
 
REFERENCES 
 
1. R. Geiss-Friedlander, F. Melchior, Concepts in sumoylation: a decade on. Nature 
reviews. Molecular cell biology 8, 947 (Dec, 2007). 
2. E. S. Johnson, Protein modification by SUMO. Annual review of biochemistry 73, 355 
(2004). 
3. K. A. Wilkinson, J. M. Henley, Mechanisms, regulation and consequences of protein 
SUMOylation. The Biochemical journal 428, 133 (Jun 1, 2010). 
4. J. Song, L. K. Durrin, T. A. Wilkinson, T. G. Krontiris, Y. Chen, Identification of a 
SUMO-binding motif that recognizes SUMO-modified proteins. Proceedings of the 
National Academy of Sciences of the United States of America 101, 14373 (Oct 5, 2004). 
5. J. J. Palvimo, PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) 
modifications and transcription. Biochemical Society transactions 35, 1405 (Dec, 2007). 
6. M. M. Rytinki, S. Kaikkonen, P. Pehkonen, T. Jaaskelainen, J. J. Palvimo, PIAS proteins: 
pleiotropic interactors associated with SUMO. Cellular and molecular life sciences : 
CMLS 66, 3029 (Sep, 2009). 
7. A. A. Yunus, C. D. Lima, Structure of the Siz/PIAS SUMO E3 ligase Siz1 and 
determinants required for SUMO modification of PCNA. Molecular cell 35, 669 (Sep 11, 
2009). 
8. Y. Azuma, A. Arnaoutov, T. Anan, M. Dasso, PIASy mediates SUMO-2 conjugation of 
Topoisomerase-II on mitotic chromosomes. The EMBO journal 24, 2172 (Jun 15, 2005). 
 
54 
 
9. H. Saitoh, J. Hinchey, Functional heterogeneity of small ubiquitin-related protein 
modifiers SUMO-1 versus SUMO-2/3. The Journal of biological chemistry 275, 6252 
(Mar 3, 2000). 
10. R. Steinacher, P. Schar, Functionality of human thymine DNA glycosylase requires 
SUMO-regulated changes in protein conformation. Current biology : CB 15, 616 (Apr 
12, 2005). 
11. Y. Galanty et al., Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to 
DNA double-strand breaks. Nature 462, 935 (Dec 17, 2009). 
12. Z. Cheng et al., Functional characterization of TIP60 sumoylation in UV-irradiated DNA 
damage response. Oncogene 27, 931 (Feb 7, 2008). 
13. B. B. Leitao, M. C. Jones, J. J. Brosens, The SUMO E3-ligase PIAS1 couples reactive 
oxygen species-dependent JNK activation to oxidative cell death. The FASEB journal : 
official publication of the Federation of American Societies for Experimental Biology,  
(Jun 15, 2011). 
14. A. F. Khelifi, M. S. D'Alcontres, P. Salomoni, Daxx is required for stress-induced cell 
death and JNK activation. Cell death and differentiation 12, 724 (Jul, 2005). 
15. E. Escobar-Cabrera et al., Characterizing the N- and C-terminal Small ubiquitin-like 
modifier (SUMO)-interacting motifs of the scaffold protein DAXX. The Journal of 
biological chemistry 286, 19816 (Jun 3, 2011). 
16. P. Salomoni, A. F. Khelifi, Daxx: death or survival protein? Trends in cell biology 16, 97 
(Feb, 2006). 
17. H. M. Shih, C. C. Chang, H. Y. Kuo, D. Y. Lin, Daxx mediates SUMO-dependent 
transcriptional control and subnuclear compartmentalization. Biochemical Society 
transactions 35, 1397 (Dec, 2007). 
18. A. M. Ishov et al., PML is critical for ND10 formation and recruits the PML-interacting 
protein daxx to this nuclear structure when modified by SUMO-1. The Journal of cell 
biology 147, 221 (Oct 18, 1999). 
19. H. Li et al., Sequestration and inhibition of Daxx-mediated transcriptional repression by 
PML. Molecular and cellular biology 20, 1784 (Mar, 2000). 
20. Q. Li et al., Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. 
Cancer research 67, 66 (Jan 1, 2007). 
 
55 
 
21. R. Croxton et al., Daxx represses expression of a subset of antiapoptotic genes regulated 
by nuclear factor-kappaB. Cancer research 66, 9026 (Sep 15, 2006). 
22. J. S. Michaelson, P. Leder, RNAi reveals anti-apoptotic and transcriptionally repressive 
activities of DAXX. Journal of cell science 116, 345 (Jan 15, 2003). 
23. L. Y. Chen, J. D. Chen, Daxx silencing sensitizes cells to multiple apoptotic pathways. 
Molecular and cellular biology 23, 7108 (Oct, 2003). 
24. M. Tewari et al., Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-
inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 
81, 801 (Jun 2, 1995). 
25. H. Ryu, Y. Azuma, Rod/Zw10 complex is required for PIASy-dependent centromeric 
SUMOylation. The Journal of biological chemistry 285, 32576 (Oct 15, 2010). 
26. T. Megidish, J. H. Xu, C. W. Xu, Activation of p53 by protein inhibitor of activated Stat1 
(PIAS1). The Journal of biological chemistry 277, 8255 (Mar 8, 2002). 
27. H. Lee et al., PIAS1 confers DNA-binding specificity on the Msx1 homeoprotein. Genes 
& development 20, 784 (Apr 1, 2006). 
28. Y. J. Song, H. Lee, PIAS1 negatively regulates ubiquitination of Msx1 homeoprotein 
independent of its SUMO ligase activity. Molecules and cells 32, 221 (Sep, 2011). 
29. J. M. Lee et al., PIAS1 enhances SUMO-1 modification and the transactivation activity 
of the major immediate-early IE2 protein of human cytomegalovirus. FEBS letters 555, 
322 (Dec 4, 2003). 
30. A. E. Carpenter et al., CellProfiler: image analysis software for identifying and 
quantifying cell phenotypes. Genome biology 7, R100 (2006). 
31. B. B. Leitao, M. C. Jones, J. J. Brosens, The SUMO E3-ligase PIAS1 couples reactive 
oxygen species-dependent JNK activation to oxidative cell death. FASEB journal : 
official publication of the Federation of American Societies for Experimental Biology 25, 
3416 (Oct, 2011). 
32. B. Liu, K. Shuai, Induction of apoptosis by protein inhibitor of activated Stat1 through c-
Jun NH2-terminal kinase activation. The Journal of biological chemistry 276, 36624 (Sep 
28, 2001). 
33. T. Kahyo, T. Nishida, H. Yasuda, Involvement of PIAS1 in the sumoylation of tumor 
suppressor p53. Molecular cell 8, 713 (Sep, 2001). 
 
56 
 
34. J. S. Michaelson, The Daxx enigma. Apoptosis : an international journal on programmed 
cell death 5, 217 (Jun, 2000). 
35. C. C. Chang et al., Structural and functional roles of Daxx SIM phosphorylation in 
SUMO paralog-selective binding and apoptosis modulation. Molecular cell 42, 62 (Apr 
8, 2011). 
36. A. Santiago, A. C. Godsey, J. Hossain, L. Y. Zhao, D. Liao, Identification of two 
independent SUMO-interacting motifs in Daxx: evolutionary conservation from 
Drosophila to humans and their biochemical functions. Cell Cycle 8, 76 (Jan 1, 2009). 
37. D. Mukhopadhyay, M. J. Matunis, SUMmOning Daxx-mediated repression. Mol Cell 42, 
4 (Apr 8, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
CHAPTER 3 
Domain analysis reveals essential domains of PIAS1 and Daxx required for 
UV-sensitivity 
 
INTRODUCTION 
SUMO E3 ligases can be grouped into four distinct families; nucleoporin RanBP2, polycomb 
protein Pc2, MMS21, and the PIAS family of SUMO E3 ligases. Of these, the PIAS (Protein 
Inhibitors of Activated Stats) are the most extensively studied and show a high degree of 
conservation across eukaryotes. Yeast have two PIAS isoforms (Siz1 and Siz2), whereas humans 
have five: PIAS1, PIASXα, PIASXβ, PIAS3 and PIASy (1). All members of the PIAS family 
have a conserved domain structure comprised of an N-terminal SAP domain, followed by a 
PINIT domain, SP-RING finger domain, SIM domain and a variable S/T rich region at the C-
terminus (1) (See Fig. 1.2, chapter 1 or Fig. 3.1, this chapter for a schematic representation of 
PIAS domain organization) 
The SAP (SAF-A/B, Acinus and PIAS) domain is a putative DNA binding domain that is 
found in many nuclear proteins. The SAP domain is comprised of a four helix bundle with strong 
affinity for DNA, but has a topology distinct from other DNA-binding domains (2). The SAP 
domain is also known to mediate interaction of PIASes with specific transcription factors (2, 3). 
In addition, our lab has recently shown that the PIASy SAP domain is essential for its 
recruitment to the centromeric region of mitotic chromosomes and this recruitment is mediated 
by an interaction between the PIASy SAP domain and the Rod/Zw10 proteins (4). The SAP 
domain is followed by a PINIT domain which is believed to be important for subcellular 
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localization of PIAS proteins as well as interaction with substrates (5). It is named after the Pro-
Ile-Asn-Ile-Thr (P-I-N-I-T) motif present in all PIAS proteins. After the PINIT domain is the SP-
RING domain (Siz/PIAS-RING). This domain is similar to the Ubiquitin E3 ligase RING (Really 
Interesting New Gene) domains and is essential for SUMO ligase activity of PIASes. The SP-
RING has been shown to interact with the SUMO E2 enzyme Ubc9 (6, 7) and is proposed to 
promote SUMO modification by forming a complex containing the substrate and the E2. The SP-
RING domain coordinates one Zn+2 ion via a tetrahedral configuration of three cysteines and one 
histidine residue. Mutation of any of the cysteines leads to a loss of SUMO ligase activity (8). 
The SIM (SUMO interacting motif) domain mediates non-covalent interactions with SUMO and 
is comprised of Val/Ile-Val/Ile-X-Val/Ile flanked either by negatively charged residues, or 
serines that can gain negative charge by phosphorylation (9). The SIM domain on PIAS is not 
essential for SUMOylation in vitro, but increases the affinity of PIAS for SUMO (8). 
The SIM domain is also found in many effector proteins that interact with SUMOylated 
proteins. Daxx has two SIM domains, one at either terminus that has been shown to mediate its 
interaction with a number of SUMOylated transcription factors (10-12). Daxx was first described 
as a pro-apoptotic protein that acts downstream of the Fas death receptor (13). Subsequent 
research has shown that Daxx localizes in the nucleus where it acts mainly as a co-repressor for 
SUMOylated transcription factors (14), but also as a transcription co-activator in some cases (10, 
15, 16). Daxx also associates with SUMOylated PML (Promyelocytic leukemia) protein. The 
two SIM domains present in Daxx can interact independently with SUMOylated proteins (10), 
albeit with different binding affinities. The Daxx N-terminal SIM has been shown to have a 
lower binding affinity towards both SUMO-1 and SUMO-2/3 compared to the Daxx C-terminal 
SIM (12). In addition to its ability to interact with SUMOylated proteins, Daxx itself has been 
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shown to be modified by SUMO (17), although a distinct SUMO E3 ligase for Daxx has not 
been identified. 
In Chapter 2, we showed that Daxx localizes to PIAS1 SUMOylated foci and depletion of 
Daxx alleviates UV-hypersensitivity induced by PIAS1 overexpression in cells. Based on these 
results, we hypothesized that the UV-hypersensitivity is dependent on Daxx recruitment to 
protein(s) specifically SUMOylated by PIAS1. This localization to SUMOylated foci and the 
resulting UV-hypersensitivity is dependent on either of the Daxx SIM domains. We also 
hypothesized that similar to PIASy, the specific localization of PIAS1 in the nucleus requires the 
PIAS1 N-terminal SAP domain and is also important for UV-hypersensitivity. In this chapter, we 
present results that validate these hypotheses. 
 
RESULTS 
PIAS1 domain deletion mutants show differences in localization 
In order to understand the importance of various PIAS1 domains for its correct localization, we 
constructed a series of deletion mutants lacking one or more PIAS1 domains. A schematic 
representation of these mutants is depicted in Figure 3.1A. The PIAS1 C-terminus truncation 
mutant N492 lacks the final 159 amino acids including the S/T-rich region, N440 lacks the C-
terminal 211 amino acids including the SIM domain and N330 is truncated at amino acid 330 
and has all domains including and downstream of the SP-RING domain deleted. The PIAS1 61C 
mutant has the first 61 amino acids deleted and thus lacks the SAP domain; the PIAS1 132C 
mutant has the first 132 amino acids deleted and starts just before the PINIT domain. All the 
mutants were expressed in HeLa cells with a C-terminal mCherry tag. The localization of these 
truncation mutants and their colocalization with SUMO2/3 in cells is compared to that of full 
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length PIAS1 in Figure 3.1B. As described earlier, PIAS1 forms distinct nuclear foci in cells. 
PIAS1 N492 mutant displays similar punctate nuclear distribution and colocalization with 
SUMO-2/3. Both PIAS1 N440 and N330 mutants fail to form foci in HeLa cell nuclei and they 
also localize in the cytoplasm. We therefore conclude that PIAS1 SIM domain is essential for 
complete nuclear retention and foci formation. The N-terminal mutants display more interesting 
nuclear localization. Both the PIAS1 61C and 132C mutants are retained completely in the 
nucleus where they form more numerous and larger foci than PIAS1 and colocalize with 
SUMO2/3. Since the PIAS1 N492 mutant looks virtually identical to PIAS1wt in localization 
and nuclear distribution, and the remaining C-terminus truncation mutants show only 
homogenous distribution in cells, we further explored only the N-terminal PIAS1 truncations that 
form nuclear foci distinct from PIAS1wt protein. 
 
 
 
 
 
Figure 3.1: PIAS1 domain deletion mutants show nuclear localization distinct from PIAS1 wt. (A) 
Diagrammatic representation of PIAS1 domain deletion mutants. N- and C-terminal truncations were designed to 
eliminate one or more PIAS1 domains. Each deletion mutant was constructed with a C-terminal mCherry tag as 
described in the methods section. (B) C-terminal mCherry-tagged PIAS1 wt and domain deletion mutants were 
expressed in HeLa cells for 24 hours. Fixed cells were stained with anti-SUMO-2/3 antibody and colocalization of 
the deletion mutants with SUMO-2/3 was analyzed. Images were acquired using a confocal microscope and a 100X 
objective. 
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PIAS1 N-terminus is required for UV-induced hypersensitivity 
The SUMO substrate selectivity of PIASes can stem from their distinct localizations within the 
cell (4, 18). We have shown earlier that PIASy localization is determined by its N-terminal SAP 
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domain. We hypothesized that the PIAS1 N-terminus may similarly be important for correct 
localization and substrate selectivity of PIAS1 and hence for the UV-hypersensitivity displayed 
by PIAS1-expressing cells. To test our hypothesis, we used the two N-terminal truncation 
mutants (61C and 132C) and an N-terminal domain-swap mutant of PIAS1 (NXα PIAS1 132C) 
that has the N-terminal 155 amino acids of PIASXα fused before the PIAS1 132C truncation 
mutant (Fig. 3.2A). We expressed these PIAS1 mutants in HeLa cells and sorted the cells as 
earlier to compare the SUMOylation profile for the mutants and PIAS1wt by immunoblotting for 
SUMO-2/3. SUMO-2/3 modifications appear less efficient in the mutants, with many of the 
higher molecular weight bands lacking in the deletion mutants (Figure 3.2B). Moreover, the 
PIAS1 N-terminal deletion mutants do not induce apoptosis in UV-treated cells (Fig. 3.2C). The 
basal cell death in cells expressing PIAS1 mutants is higher in the mock-irradiated samples, but 
there is no significant increase in apoptosis four hours after UV irradiation. More significantly, 
fusing N-terminus of PIASXα to PIAS1 132C truncation mutant does not restore the UV-
hypersensitivity of cells. Once again, we calculated the apoptotic ratio by normalizing UV 
irradiation-induced apoptosis to apoptosis in mock-irradiated cells and we see three-fold more 
apoptosis in cells expressing PIAS1wt when compared to cells expressing PIAS1 N-terminal 
deletion mutants (Fig. 3.2D). These results indicate the importance of the PIAS1 N-terminal 
domain in substrate selection and in UV-hypersensitivity.  
 
Figure 3.2: PIAS1 N-terminal SAP domain is essential for correct localization and UV-hypersensitivity. (A) 
Diagrammatic representation of PIAS1 N-terminal truncation and domain swap mutant design. The truncation and 
the PIASXα domain swap mutants were designed with a C-terminal mCherry fusion, as described in the methods 
section. (B) PIAS1 N-terminal is required for correct substrate modification. Cell expressing PIAS1 wt or 
truncation/swap mutants were sorted based on mCherry signal and the SUMOylation profile was analyzed by 
immunostaining with anti-SUMO-2/3 antibody. Anti-DsRed antibody marks the mCherry-tagged PIAS1 or PIAS1 
truncation mutants and anti-β-actin antibody has been used as a loading control. (C) PIAS1 mutants lacking the 
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PIAS1 N-terminus do not increase apoptosis following UV irradiation. The plotted values are an average of four 
independent experiments. The error bars represent 1 standard error of the mean. (D) Apoptotic ratio was determined 
by plotting the ratio of the percentage of apoptotic cells after UV-irradiation over the percentage of apoptotic cells in 
mock-irradiated samples, using values calculated for (C). 
 
 
 
In chapter 2, we showed that some of the PIAS1 foci colocalize with PML and some with Daxx, 
but the two colocalizations are mostly independent of one another. In contrast to PIAS1wt, the 
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two PIAS1 truncation mutants showed strong colocalization with PML-NBs and disrupted Daxx 
distribution in cells (Fig. 3.3). PIAS1 61C showed weak colocalization with Daxx in the PML 
bodies, but PIAS1 132C failed to colocalize with Daxx completely. The NXα PIAS1 132C 
mutant showed much reduced localization with PML bodies, but also failed to localize 
significantly with Daxx (Fig. 3.3). These results indicate that the N-terminus of PIAS1 is 
required for correct localization in the nucleus and for recruitment of Daxx to SUMOylated foci.  
 
 
 
Figure 3.3: PIAS1 N-terminal mutants localize preferentially to PML-bodies but do not colocalize with Daxx. 
C-terminal mCherry-tagged PIAS1wt, PIAS1 61C, 132C and NXα 132C mutants were expressed in HeLa cells for 
24 hours. Fixed cells were stained with anti-Daxx and anti-PML antibodies. Images were acquired using a confocal 
microscope with a 100X objective. 
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Daxx C-terminal SIM domain is important for PIAS1-mediated UV-hypersensitivity 
Daxx is also known to be SUMOylated in cells. Over 15 different lysines in Daxx can be 
modified, primarily by SUMO-1 (11).  Using immunoblotting, we investigated whether any of 
the PIASes can act as SUMO E3 ligases for Daxx. We could not detect higher molecular weight 
bands in any of the PIAS-transfected cells, which indicates that Daxx is not a major 
SUMOylated protein in PIAS-expressing cells (Fig. 3.4A).Daxx has two SUMO Interacting 
Motifs (SIM); one at each terminus. The SIMs allow Daxx to interact with SUMOylated proteins 
including PML and a number of transcription factors. The two SIM domains have been shown to 
display different affinities for SUMO (12). In order to understand the requirement of either Daxx 
SIM domain for PIAS1-mediated UV-hypersensitivity, we first constructed RNAi-resistant Daxx 
by introducing five silent mutations in the Daxx DNA in a stretch of base pairs targeted by Daxx 
siRNA. Figure 3.4B shows that this protein is resistant to Daxx siRNA induced degradation. 
Daxx SIM deletion mutants were constructed from the RNAi-resistant Daxx (Fig. 3.4C) and 
expressed along with PIAS1 in HeLa cells treated with Daxx siRNA.  
 
 
Figure 3.4: Analysis of Daxx SUMOylation and expression of Daxx SIM truncation mutants. (A) Daxx does 
not appear to be a major SUMOylation substrate. HeLa cells were transfected with each of the PIAS isoforms. Mock 
and UV-treated cells were sorted based on mCherry signal and lysates were immunostained with anti-Daxx antibody 
after western blotting. Anti-β-actin was used as a loading control. (B) RNAi resistant Daxx was made by introducing 
five silent mutations in Daxx cDNA in the region affected by siRNA1. HeLa cells expressing empty vector, Daxx, 
or RNAi resistant Daxx were treated with either control siRNA or Daxx siRNA for 48 hours. Whole cell extracts 
were probed with anti-Daxx antibody after western blotting. β-actin was used as a loading control. (C) Daxx siRNA-
treated, mock irradiated or UV-irradiated samples of HeLa cells expressing either PIAS1mCherry alone or in 
combination with Myc-tagged RNAi-resistant Daxx fl or Daxx SIM deletion mutants were tested for the presence of 
Daxx and PIAS1 by probing with anti-Myc-tag antibody or anti-DsRed antibody, respectively. β-actin was used as a 
loading control. 
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The exogenously expressed Daxx, and Daxx N-terminal SIM deletion mutant (dNSIM), form 
distinct foci in cells that colocalize with PIAS1 (Fig. 3.5A and B). The Daxx C-terminal SIM 
deletion mutant (dCSIM) and the Daxx deletion mutant lacking both the SIMs (dSIMs) fail to 
form distinct foci and thus do not show colocalization with the PIAS1 foci (Fig. 3.5A and B). As 
expected, PIAS1 expression alone in Daxx siRNA-treated cells did not increase apoptosis 
following UV irradiation (Fig. 3.5C). We saw a more than two-fold increase in the percentage of 
apoptotic cells when RNAi resistant Daxx was expressed in addition to PIAS1 in Daxx siRNA-
treated cells. Expression of Daxx lacking the dNSIM mutant also increased apoptosis to a similar 
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extent. However, expression of Daxx lacking the C-terminal SIM (dCSIM) or both the SIMs 
(dSIMs) failed to increase apoptosis in PIAS1-expressing cells. These results indicate that Daxx 
C-terminus SIM is important for PIAS1-mediated hypersensitivity to UV irradiation. Together, 
these results indicate that Daxx is recruited to PIAS1 foci by interaction with PIAS1-
SUMOylated substrates via its C-terminal SIM domain and that this recruitment of Daxx, and 
probably not Daxx SUMOylation itself, is important for PIAS1-mediated UV-induced apoptosis 
in cells. 
 
 
Figure 3.5 Daxx C-terminal SIM domain is required for PIAS1-mediated UV-hypersensitivity. (A) 
Diagrammatic representation of Daxx SIM domain truncation mutants. The truncation mutants were designed as 
described in the methods section.  Daxx dNSIM mutant lacks the first 17 amino acids, dCSIM lacks the final 20 
amino acids, and dSIMs mutant lacks both the first 17 amino acids and the last 20 amino acids, thus eliminating both 
SIM domains from Daxx. All Daxx constructs have an N-terminal Myc-tag. (B) Daxx C-terminal SIM domain is 
essential for proper Daxx localization. HeLa cells transfected with the bicistronic vector carrying PIAS1-mCherry 
and Myc-Daxx or Myc-Daxx truncations. Fixed cells were stained with anti-Myc-tag antibody. Images were 
acquired using a confocal microscope using a 100X objective. Scale bar: 5 μm.  (C) Expression of Daxx C-terminal 
SIM deletion mutants rescues UV-hypersensitivity phenotype in PIAS1 expressing cells. Apoptotic cells were 
counted as described in the methods section. The plotted values are an average of three independent experiments. 
The error bars represent 1 s.e.m. 
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DISCUSSION 
PIASes have highly conserved domain organization, yet show selectivity towards their 
substrates. Reindle et al. (19) have shown that in the case of the yeast SUMO E3 ligases Siz1 and 
Siz2, the localization of the ligases dictates the substrate selectivity. In chapter 2, we showed that 
the UV-hypersensitivity phenotype is specific to PIAS1. We also showed that each of the PIASes 
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shows a unique nuclear distribution and appears to have a unique subset of substrates.  Based on 
these results, we hypothesized that PIAS1’s distinctive localization and the resulting substrate 
selectivity are responsible for the PIAS1-specific cellular response to UV irradiation. This 
hypothesis is supported by the results that the PIAS1 N-terminus truncation mutants that are 
retained in the nucleus but do not display the same localization pattern as wild-type PIAS1, do 
not activate apoptosis in response to UV irradiation. This localization-dependent regulation of 
SUMO ligase activity is consistent with our published results showing PIAS4/y mediates mitotic 
chromosomal SUMOylation in Xenopus egg extract assays (4, 18). We have earlier shown that 
PIASy’s centromeric localization to the mitotic chromosome requires it’s N-terminal SAP 
domain (4). We show a similar requirement of the PIAS1 N-terminus for its correct localization 
and SUMOylation activity. Mutants lacking PIAS1 SAP domain localize preferentially to PML 
bodies and do not display the same SUMOylation profile as PIAS1wt. PIAS1 SAP domain 
deletion mutants also fail to elicit sensitivity to UV irradiation. The PIAS1 N-terminus domain is 
specifically required for UV-hypersensitivity; a substitution of the domain with the equivalent 
domain from PIASXα does show localization similar to PIAS1wt and also does not cause 
increased cell death following UV irradiation. The PIASy SAP domain specifically binds to the 
Rod/Zw10 proteins and this interaction is required for localizing PIASy to the centromere in 
mitotic chromosomes. It will be interesting to see if the PIAS1 SAP domain also has specific 
binding partner(s) that recruit it to distinct nuclear foci. 
 In chapter 2 we showed that Daxx is a mediator of UV-hypersensitivity caused by PIAS1 
overexpression in cells. Daxx can both interact with SUMOylated proteins and can be 
SUMOylated in cells. Fifteen different lysine residues can be potentially SUMOylated in vitro, 
however, mutation of these residues has not been shown to have any effect on Daxx’s 
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localization or function as a transcriptional regulator (11). On the other hand, the Daxx C-
terminal SIM domain has been shown to be essential for recruitment of Daxx to PML bodies and 
SUMOylated transcription factors (11). Our data also suggests that Daxx C-terminal SIM is 
essential for its recruitment to PIAS1 SUMOylated foci and also for PIAS1-induced UV 
hypersensitivity. Overexpression of Daxx C-terminal SIM truncation mutant in cells treated with 
Daxx RNAi leads to a loss of PIAS1-induced UV hypersensitivity. Cells expressing of Daxx N-
terminal SIM truncation mutant along with PIAS1 undergo cell death after UV irradiation.  
 Many different transcription factors are known to be SUMOylated and Daxx has been 
shown to regulate gene expression by both acting as a repressor and an activator of transcription 
from SUMOyalted transcription factors. Our results suggest a similar mechanism for PIAS1-
induced UV hypersensitivity, where PIAS1-mediated SUMOylation of specific substrates may 
lead to recruitment of Daxx and changes in gene regulation that sensitize cells to UV irradiation. 
This premise is further explored in the next chapter. 
 
EXPERIMENTAL PROCEDURES 
DNA constructs and cell transfection: PIAS1 truncations were amplified from full length 
PIAS1 cloned into pCDNA4 his maxC mCherry vector described in chapter 2. The amplified 
PIAS1 truncation fragments were cloned into the same vector, so that expressed proteins will 
have a C-terminal mCherry fusion. NXα-PIAS1 132C was constructed by amplifying the DNA 
encoding the first 155 amino acids of PIASXα and inserting it into the EcoRI site preceding the 
PIAS1 132C DNA. Daxx cDNA was amplified from HeLa cells and cloned between NheI and 
EcoRI sites in pEGFPC1 vector (Clontech Laboratories Inc., Mountain View, CA). The Daxx 
RNAi-resistant mutant was generated by introducing 5 silent mutations in Daxx DNA [(620-
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aaaaagaattggatctttcagagttagatga-650, the mutations are underlined] that disrupt 
Daxx siRNA (DAXX-HSS102654, Invitrogen, Carlsbad, CA) binding  using the Quikchange II 
XL Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA).  Daxx SIM deletion 
mutants were created by amplifying Daxx DNA coding for amino acids 18-740 (dNSIM), 1-720 
(dCSIM) and 18-720 (dSIMs). A Myc-tagged RNAi-resistant Daxx and Daxx deletion mutants 
were cloned into the multiple cloning site-A of the bicistronic pIRES vector (Clontech 
Laboratories Inc., Mountain View, CA). HeLa cells were grown to 50% confluence in McCoy’s 
medium (Mediatech Inc., Manassas, VA) that was supplemented with 10% FBS and transfected 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as per manufacturer’s instructions.  
UV irradiation and apoptotic assays: The transfected HeLa cells were either mock-irradiated 
or irradiated with 30 J/m2 of UV using an Entela UV crosslinker. In brief, the cells were washed 
twice with PBS and then irradiated in PBS. After irradiation, the PBS was removed and replaced 
with growth medium. The cells were analyzed 4 hours or 24 hours after UV irradiation. Cells 
that were grown on coverslips were fixed with 4% paraformaldehyde and permeabilized using 
0.2% Triton-X-100. The cells were then stained with an anti-Parp1 antibody and Hoechst 33342 
dye (which stains DNA) for immunofluorescence analysis. Apoptotic cells were counted based 
on DNA morphology and the re-distribution of Parp1 into the cytoplasm.  
Cell sorting and Western blot analysis: HeLa cells that were transfected with mCherry-tagged 
PIAS family members were sorted from the untransfected cells using a Beckman Coulter MoFlo 
XDP sorter  (Fort Collins, CO) with a 488 nm excitation filter and a 620/29 nm emission filter. 
The sorting was performed 4 hours after the mock or UV irradiation. The sorted cells were 
subjected to a Western blot analysis, and the protein levels were normalized by staining for β-
actin (Cell Signaling Technology, Danvers, MA). 
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Immunofluorescence analysis: Transfected and treated cells were fixed with 4% 
paraformaldehyde and permeabilized using 0.2% Triton-X-100. The cells were then blocked for 
15 min with 5% BSA and 2.5% fish gelatin that was prepared in PBST. After washing, the cells 
were stained with the appropriate antibody following the manufacturer’s dilution instructions for 
one hour, which was followed by staining with an Alexa dye-tagged secondary antibody 
(Invitrogen, Carlsbad, CA) and Hoechst 33342 dye. The cells were mounted using Vectashield 
mounting medium (Vector Laboratories, Burlingame, CA), imaged using a DSU-10 spinning 
disk (Yokugawa-type) confocal microscope that was equipped with an Olympus 100X objective 
(with a numerical aperture of 1.45), Hamamatsu EMCCD and the Slidebook imaging package 
(Intelligent Imaging Innovations, Denver, CO). An anti-human Daxx antibody was purchased 
from Sigma and an anti-PML antibody and the anti-Myc-tag antibody from SantaCruz 
Biotechnology Inc. (Santa Cruz, CA). The other antibodies that were used in this study were 
generated in the lab. 
Daxx silencing using siRNAs: siRNAs against human Daxx were obtained from Invitrogen 
(Carlsbad, CA) (siRNA1: DAXX-HSS102654 and siRNA2: DAXX-HSS175936). HeLa cells 
were transfected with 200pmols of either siRNA using Lipofectamine RNAiMAX (Invitrogen, 
Carlsbad, CA) using the reverse transfection method, as described by the manufacturer. The cells 
were plated to obtain a next-day confluency of 50%. Twenty-four hours after the siRNA 
transfection, the cells were transfected with pCDNA4 His maxC PIAS1 mCherry or the 
bicistronic pIRES contruct expressing PIAS1 and Myc-tagged RNAi resistant Daxx or Daxx 
truncation mutants. The cells were UV-irradiated 48 hours after the siRNA treatment as 
described above, and the apoptotic cells were counted 4 hours later. 
 
 
 
73 
 
REFERENCES 
 
1. M. M. Rytinki, S. Kaikkonen, P. Pehkonen, T. Jaaskelainen, J. J. Palvimo, PIAS proteins: 
pleiotropic interactors associated with SUMO. Cellular and molecular life sciences : 
CMLS 66, 3029 (Sep, 2009). 
2. S. Okubo et al., NMR structure of the N-terminal domain of SUMO ligase PIAS1 and its 
interaction with tumor suppressor p53 and A/T-rich DNA oligomers. The Journal of 
biological chemistry 279, 31455 (Jul 23, 2004). 
3. S. Sachdev et al., PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 
activity by sequestration into nuclear bodies. Genes & development 15, 3088 (Dec 1, 
2001). 
4. H. Ryu, Y. Azuma, Rod/Zw10 complex is required for PIASy-dependent centromeric 
SUMOylation. The Journal of biological chemistry 285, 32576 (Oct 15, 2010). 
5. D. Duval, G. Duval, C. Kedinger, O. Poch, H. Boeuf, The 'PINIT' motif, of a newly 
identified conserved domain of the PIAS protein family, is essential for nuclear retention 
of PIAS3L. FEBS letters 554, 111 (Nov 6, 2003). 
6. T. Kahyo, T. Nishida, H. Yasuda, Involvement of PIAS1 in the sumoylation of tumor 
suppressor p53. Molecular cell 8, 713 (Sep, 2001). 
7. Y. Takahashi, Y. Kikuchi, Yeast PIAS-type Ull1/Siz1 is composed of SUMO ligase and 
regulatory domains. The Journal of biological chemistry 280, 35822 (Oct 28, 2005). 
8. A. A. Yunus, C. D. Lima, Structure of the Siz/PIAS SUMO E3 ligase Siz1 and 
determinants required for SUMO modification of PCNA. Molecular cell 35, 669 (Sep 11, 
2009). 
9. A. Minty, X. Dumont, M. Kaghad, D. Caput, Covalent modification of p73alpha by 
SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins 
and a SUMO-1 interaction motif. The Journal of biological chemistry 275, 36316 (Nov 
17, 2000). 
10. A. Santiago, A. C. Godsey, J. Hossain, L. Y. Zhao, D. Liao, Identification of two 
independent SUMO-interacting motifs in Daxx: evolutionary conservation from 
Drosophila to humans and their biochemical functions. Cell Cycle 8, 76 (Jan 1, 2009). 
 
74 
 
11. D. Y. Lin et al., Role of SUMO-interacting motif in Daxx SUMO modification, 
subnuclear localization, and repression of sumoylated transcription factors. Molecular 
cell 24, 341 (Nov 3, 2006). 
12. E. Escobar-Cabrera et al., Characterizing the N- and C-terminal Small ubiquitin-like 
modifier (SUMO)-interacting motifs of the scaffold protein DAXX. The Journal of 
biological chemistry 286, 19816 (Jun 3, 2011). 
13. X. Yang, R. Khosravi-Far, H. Y. Chang, D. Baltimore, Daxx, a novel Fas-binding protein 
that activates JNK and apoptosis. Cell 89, 1067 (Jun 27, 1997). 
14. P. Salomoni, A. F. Khelifi, Daxx: death or survival protein? Trends in cell biology 16, 97 
(Feb, 2006). 
15. A. V. Emelyanov, C. R. Kovac, M. A. Sepulveda, B. K. Birshtein, The interaction of 
Pax5 (BSAP) with Daxx can result in transcriptional activation in B cells. The Journal of 
biological chemistry 277, 11156 (Mar 29, 2002). 
16. Y. S. Huang, H. M. Shih, Daxx positively modulates beta-catenin/TCF4-mediated 
transcriptional potential. Biochemical and biophysical research communications 386, 762 
(Sep 4, 2009). 
17. M. S. Jang, S. W. Ryu, E. Kim, Modification of Daxx by small ubiquitin-related 
modifier-1. Biochemical and biophysical research communications 295, 495 (Jul 12, 
2002). 
18. Y. Azuma, A. Arnaoutov, T. Anan, M. Dasso, PIASy mediates SUMO-2 conjugation of 
Topoisomerase-II on mitotic chromosomes. The EMBO journal 24, 2172 (Jun 15, 2005). 
19. A. Reindle et al., Multiple domains in Siz SUMO ligases contribute to substrate 
selectivity. Journal of cell science 119, 4749 (Nov 15, 2006). 
 
 
 
 
 
 
 
 
75 
 
CHAPTER 4 
 Exploring downstream targets of PIAS1: Potential regulation of 
NFκB pathway 
 
INTRODUCTION 
SUMOylation can regulate gene expression via modification of transcription factors, their co-
regulators and chromatin modifiers. Other than a few exceptions, SUMO modification of 
transcription factors has an inhibitory effect on their activity (1). PIASes (Protein Inhibitors of 
Activated Stat) were initially identified as proteins that can inhibit function of members of the 
Stat family of transcription factors (2, 3). PIAS proteins interact with many different proteins, a 
large number of which are transcription factors. In addition to acting as a SUMO E3 ligase for 
many of these transcription factors, PIASes have also been shown to regulate the activity of 
some transcription factors in a SUMO-ligase independent manner (described in Chapter 1) (4). 
Thus, PIASes are also transcriptional regulators.  
The NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) transcription 
factors are dimers of Rel Homology Domain (RHD) containing proteins and play important roles 
in regulation of cell survival, immune responses, differentiation and development. The NFκB 
family consists of five members that can be segregated into two groups. The first group consists 
of RelA (p65), RelB and c-Rel proteins; the second group includes repressive precursor proteins 
p105 and p100 that are processed to the transcriptionally active forms p50 and p52, respectively. 
The p105 protein is constitutively cleaved to its active form p50, whereas the p100 protein is 
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cleaved only when activating stimuli are received by specific cell surface receptors. These 
proteins can form fifteen different homo- or heterodimers, only nine of which (RelA:p50, 
RelA:p52, RelB:p50, RelB:p52, c-Rel:p50, c-Rel:p52, c-Rel:RelA, c-Rel:c-Rel, and  RelA:RelA) 
have DNA-binding and transcription regulation activities (see Figure 4 below). In the canonical 
pathway, NFκB dimers are held inactive in the cytoplasm by the IκB (Inhibitors of NFκB) family 
of inhibitory proteins. Activating stimuli leads to phosphorylation of IκB proteins by IκB kinases 
(IKK) and Ubiquitin mediated degradation that then allows for the translocation of NFκB dimers 
(mainly RelA:p50) to the nucleus. 
 
The non-canonical or alternate pathway involves the p52 precursor p100 and RelB. Both 
p105 and p100 proteins contain IκB-like domains in their C-terminus. p100 binds to RelB in the 
cytoplasm. An activating stimulus leads to stabilization of the NFκB-Inducing-Kinase (NIK) that 
in turn phosphorylates p100. Phosphorylation causes proteolytic cleavage of p100 to the active 
p52 form. The RelB:p52 dimer then translocates to the nucleus where it acts as a transcription 
regulator. The kinetics of the canonical and the non-canonical pathways is very different. The 
canonical NFκB pathway is a rapid but transient response to activating stimuli. The non-
canonical NFκB response on the other hand develops slowly but persists for a longer period (5).  
Figure 4.0: NFκB family of 
transcription factors. The members of 
the NFκB family of transcription factors 
can form 15 different dimers of which 9 
are transcriptionally active (highlighted in 
yellow). Image modified from Ellen 
O’Dea and Alexander Hoffman, 
Regulatory logic of the NF-κB signaling 
system (2009) Cold Spring Harbor 
Perspectives in Biology. 
 
77 
 
 Daxx has been shown to repress the transcriptional activity of both RelA (6) and RelB 
(7). In the case of RelA, Daxx binding has been shown to inhibit CBP-mediated acetylation and 
activation of RelA (6). Interaction of Daxx with RelB has been shown to repress transcription of 
a subset of anti-apoptotic genes and involves recruitment of DNA methyl transferase enzyme 1 
(DNMT1) to RelB promoters (7, 8). Daxx has two SUMO interaction motifs (SIMs) and 
interacts with and represses many SUMOylated transcription factors, but the role of 
SUMOylation in the interaction of Daxx with RelA or RelB has not been tested.  
 Based on the data presented in chapter 2 and 3, we hypothesized that the expression of 
PIAS1 in cells changes the balance of pro- and anti-apoptotic factors. We tested our hypothesis 
by analyzing the transcription levels of several pro- and anti-apoptotic proteins. Expression data 
reveals the NFκB pathway to be an important target of PIAS1 in cells. These results are 
presented and discussed in this chapter. 
RESULTS 
Exogenous expression of PIAS1 in HeLa cells affects the transcription of both pro- and 
anti-apoptotic genes 
 In order to test our hypothesis that PIAS1 expression imbalances the levels of pro- and anti-
apoptotic factors, we first evaluated the levels of transcripts of the Bcl2 family of apoptosis-
related proteins. The Bcl2 family consists of both pro- and anti-apoptotic proteins that regulate 
the intrinsic or mitochondrial pathway of apoptosis. Total RNA was purified from sorted 
mCherry or PIAS1-mCherry expressing cells. DNA fragments corresponding to the anti-
apoptotic (Bcl2, Bcl-xl and Mcl-1) and pro-apoptotic (Bax-α, Bak and Bik) Bcl2 family 
members was amplified from the cDNA using exon-specific primers restricted to a single exon. 
Levels of transcripts from mCherry- and PIAS1-mCherry-expressing cells were compared from 
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three replicates based on their intensity on agarose gels. We did not see differences between the 
levels of transcripts of any of the Bcl2 family members between mCherry- and PIAS1 mCherry-
expressing cells (Figure 4.1A). This result led us to conclude that the Bcl2 family may not be 
regulated by PIAS1 and Daxx.  
  In order to analyze a larger set of apoptosis-related transcripts, we used the RT2 Profiler 
PCR Array (SA Biosciences/ Qiagen) that can screen for expression levels of 84 apoptosis-
related genes. Three independent PCR arrays were performed and only the genes whose 
expression levels were observed to be changed consistently in each array in response to PIAS1 
overexpression were considered for further analysis. The result of this analysis is summarized in 
Figure 4.1B and Table 4.1 and discussed in further detail in the next subsection. Briefly, we saw 
higher than three-fold change in the expression levels of a number of apoptosis-related genes 
from cells expressing PIAS1. More significantly, we saw an increase in the levels of pro-
apoptotic transcripts CASP14 and CD40, and a decrease in the levels of anti-apoptotic transcripts 
BIRC3, XIAP, and a protein important for apoptosis regulation following UV irradiation, 
Gadd45α. A detailed analysis of these results is presented in the next subsection. 
 We would like to clarify at this point that the results from the apoptotic PCR array is only 
being used a guide for designing further experiments. These results will be verified 
independently by quantitative reverse-transcriptase PCR for each of the genes that show a 
reproducible change in gene expression and also by analyzing the protein-levels in PIAS1-
expressing cells using specific antibodies. 
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Figure 4.1: PIAS1 expression leads to changes in transcript level of several apoptosis related genes. (A) 
Relative mRNA amounts of pro- and anti-apoptotic Bcl-2 family genes from cells expressing mCherry or PIAS1 
does not vary significantly. HeLa cells transfected with mCherry or PIAS1 were sorted. Total cellular RNA was 
extracted from cells and used to amplify anti- (Bcl2, Bcl-xl, Mcl1) and pro- (Bax-α, Bak, Bik) apoptotic Bcl-2 
family genes. RNA amounts were quantified by measuring band intensities on agarose gel and normalized with β-
actin. The plotted values are an average of three independent experiments. The error bars represent 1 s.e.m. (B) 
Apoptosis array data reveals several apoptosis related genes whose transcript level is modulated after PIAS1 
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expression. mCherry or PIAS1 transfected HeLa cells were sorted, total cellular RNA was purified, and expression 
of 84 apoptosis related genes was analyzed using real-time PCR analysis. Gene expression was analyzed using web-
based analysis software from SA Biosciences. The software performs ΔΔCT based fold-change calculations from 
uploaded raw threshold cycle (CT) data. CT values obtained from mCherry-expressing cells were used as a control 
group. Expression data was normalized using house-keeping genes β-2-microglobulin (B2M) and hypoxanthine 
phosphoribosyl transferase1 (HPRT1). Fold change was calculated as 2(-ΔΔCT); all fold change values greater than 1 
were reported as fold upregulation and for fold-change values less than 1, the negative inverse of the result was 
reported as fold downregulation. Three independent experiments were performed, and only genes showing at least a 
2 fold change in gene expression are shown in the figure.  
 
Table 4.1: Apoptosis-related transcripts regulated by expression of PIAS1 in HeLa cells. 
Gene Pro/Anti Apoptotic Fold Regulation Transcription regulated by 
NFκB 
BCL2L10 Anti 3.66 No 
BCL2L2 Anti -5.31 No 
BIRC3 Anti -3.52 Yes (RELB) 
XIAP Anti -4.56 Yes (RELB) 
CASP14 Anti 7.56 Yes (RELB) 
CD40 Pro 7.02 Yes 
DAPK1 Pro -3.26 Yes (RELB) 
FADD Pro -3.3 No 
FASLG Pro 3.56 No 
GADD45A Anti -5.36 Yes* (see text below) (RELB) 
LTBR Pro -3.47 Yes 
TNFRSF11B Anti -7.2 Yes 
TNFRSF21 Pro -6.46 No 
TRAF2 Anti -5.03 Yes 
TRAF3 Anti -3.34 Yes 
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PIAS1 expression potentially regulates the NFκB pathway 
In chapters 2 and 3, we showed that PIAS1 recruits Daxx to SUMOylated foci and recruitment of 
Daxx is required for PIAS1-induced UV hypersensitivity. Daxx binds to SUMOylated 
transcription factors and acts as a co-repressor (9, 10). To identify any transcription factors that 
might be common to the gene transcripts down- or up-regulated by PIAS1 expression in cells, we 
used a bioinformatics search engine from SA Biosciences that catalogs known regulatory 
elements upstream of genes included in their microarrays. We found that 9 out of 15 genes 
whose expression levels changed consistently in response to PIAS1 overexpression are known to 
be directly regulated by the NFκB family of transcription factors (see Table 4.1). Expression of 
four of the genes, Birc3, XIAP, DAPK (7, 8), and Caspase14 (11), has been shown to be 
regulated by RelB. Of these, Birc3 and XIAP are anti-apoptotic whereas DAPK is pro-apoptotic. 
Caspase14 is expressed in differentiated keratinocyte and plays a protective role against UV 
radiation (12, 13).  
 Two other down-regulated genes that are regulated by NFκB at the transcriptional level, 
TRAF2 and TRAF3 (Tumor necrosis factor receptor associated factor), have been shown to be 
important regulators of the non-canonical NFκB (RelB) pathway. TRAF2 and TRAF3 form a 
multi-component Ubiquitin ligase (TRAF2-TRAF3-cIAP E3 ligase) that negatively regulates the 
levels of NIK (NFκB inducing kinase) in the cells. Receptor stimulation leads to degradation of 
the Ubiquitin ligase components. This reduces NIK turnover in cells and increases the levels of 
NIK. NIK-induced p100 phosphorylation and subsequent proteolytic processing generates the 
active p52 that translocates with RelB to the nucleus. Genetic deficiencies in TRAF2 or TRAF3 
cause accumulation of NIK and aberrant p100 processing (5). Thus, RelB translocation might be 
upregulated in PIAS1 expressing cells due reduced levels of TRAF2 and TRAF3. 
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TNFRSF11b (tumor necrosis factor receptor superfamily, member 11b) acts as an anti-
apoptotic protein by inhibiting TRAIL binding to its receptors (TRAIL-R1/R2) (14). TRAIL has 
been shown to activate apoptosis in response to UV irradiation (15). TNFRSF11b also acts as an 
inhibitor of RANKL (Receptor activator of NFκB ligand)-RANK interaction by sequestering 
RANKL. Both RANK and CD40 receptors activate non-canonical NFκB pathway strongly by 
binding to TRAF3 and inducing NIK stabilization (16). Thus, a downregulation of TNFRSF11b, 
which itself is regulated by NFκB at the transcriptional level, can both sensitize cells to UV and 
upregulate RelB translocation to the nucleus. 
 Gadd45α is a member of the GADD family (Growth arrest and DNA damage inducible) 
of genes that have been shown to be important modulators of DNA damage response and act by 
initiating growth arrest, DNA repair and regulating cell death or survival (17). Gadd45α 
expression is stimulated by UV irradiation. Both the canonical and the non-canonical NFκB 
pathways can downregulate Gadd45α transcription indirectly by increasing c-Myc transcription. 
c-Myc acts as a transcriptional co-repressor of C/EBP-α mediated Gadd45α transcription (17). In 
different studies, Gadd45α has been shown to both activate and suppress apoptosis by activation 
of p38 MAPK pathway in a cell-type specific manner (18, 19). Interestingly, Gadd45α mediated 
suppression of apoptosis by p38 activation also involves the activation of the canonical NFκB 
pathway (20). 
 Taken together, our data suggest that the NFκB pathway is a potential regulatory target of 
exogenous PIAS1 expression in cells. Changes in the NFκB pathway may contribute directly to 
PIAS1 induced UV hypersensitivity. 
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RelB interacts with PIAS1 and Daxx in HeLa cells overexpressing PIAS1 
Since our PCR array data point to an involvement of the NFκB pathway in PIAS1 mediated UV 
hypersensitivity, we decided to test for a direct interaction between PIAS1 and NFκB members. 
We expressed PIAS1-mCherry or PIAS1 132C-mCherry (truncation mutant lacking the PIAS1 
SAP domain) in HeLa cells and then used the cell-permeable reversible protein cross-linker 
DTBP (dimethyl 3, 3'-dithiobispropionimidate) to crosslink interacting proteins. We 
immunoprecipitated crosslinked proteins using anti-PIAS1 or anti-Daxx antibody (Figure 4.2). 
As expected, we were able to co-immunoprecipitate (Co-IP) Daxx using an anti-PIAS1 antibody 
that recognizes the C-terminus of PIAS1 from PIAS1 cell lysate. We could also co-
immunoprecipitate (IP) significantly lesser amounts of Daxx from PIAS1 132C lysate, though 
we suspect that this could be due to immunoprecipitation of endogenous PIAS1 along with 
overexpressed PIAS1 132C truncation. Conversely, we were able to coimmunoprecipitate 
PIAS1-mCherry with Daxx using anti-Daxx antibody, but not PIAS1 132C mCherry. This agrees 
with our immunofluorescence data that PIAS1, but not PIAS1 132C, shows significant 
colocalization with Daxx in cells. We detected minimal amounts of RelA in both anti-PIAS1 and 
anti-Daxx IP and there are no differences between the PIAS1 and PIAS1 132C lysates. We could 
detect significant enrichment of RelB in both anti-PIAS1 and anti-Daxx IP from PIAS1 lysate 
compared to PIAS1 132C lysate (Figure 4.2). (Some RelB was immunoprecipitated non-
specifically with rabbit IgG. Although we could immunoprecipitate PIAS1 132C less efficiently 
compared to PIAS1wt using PIAS1 antibody, we do see an enrichment of RelB in IP from 
PIAS1-lysate over the background level. RelB co-immunoprecipitated with PIAS1 132C is not 
significantly higher than the non-specific immunoprecipitation we see with IgG). This result 
shows that there is significant association of RelB with Daxx and PIAS1 in cells exogenously 
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expressing PIAS1. Overall, our data suggests that exogenously expressed PIAS1 is able to recruit 
RelB and Daxx to a common focus where these proteins potentially interact. 
 
 
Figure 4.2: The NFκB family protein RelB interacts with PIAS1 and Daxx in HeLa cells expressing PIAS1. 
Cells expressing PIAS1 or PIAS1 132C deletion mutant were treated with the cell permeable reversible crosslinker 
DTBP before lysis. Immunoprecipitation was performed using anti-PIAS1 antibody or anti-Daxx antibody and 
rabbit IgG was used as control. Anti-PIAS1 antibody could co-immunoprecopitate RelB in more amounts from 
PIAS1-expressing cell lysate compared to PIAS1 132C lysate. Similarly, anti-Daxx antibody could co-
immunoprecipitate more RelB from PIAS1 lysate than from PIAS1 132C lysate. RelA was immunoprecipitated at 
similar levels by anti-PIAS1 and anti-Daxx antibodies from both PIAS1 and PIAS1 132C lysates.  
 
 
DISCUSSION 
Our data suggests that PIAS1 interacts with NFκB pathway protein RelB in cells. We see 
significant differences in PIAS1:RelB and Daxx:RelB interaction from cells expressing the 
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PIAS1wt or PIAS1 132C mutant. RelB shows a stronger interaction with PIAS1wt and also with 
Daxx in PIAS1wt expressing cells. Thus RelB appears to be a relevant target of exogenously 
expressed PIAS1 in cells. 
The canonical NFκB pathway is known to be regulated by PIAS1 (21). RelA DNA 
binding activity is inhibited by PIAS1. This inhibition requires PIAS1 SUMO E3 ligase activity, 
although PIAS1 itself has not been shown to SUMOylate RelA (21). Instead, RelA was shown to 
be SUMOylated by PIAS3 and this modification results in repression of NFκB transcriptional 
activity (22). On the other hand, PIAS1-null cells show increased expression of certain RelA 
regulated genes (21). Daxx also regulates RelA transcriptional activity, though the mechanism 
described does not involve RelA SUMOylation (6). Our data shows that both PIAS1 and the 
PIAS1 132C mutant is able to interact with endogenous RelA and that interaction of endogenous 
Daxx with RelA is not affected by the expression of either the wildtype or the mutant PIAS1 
(Figure 4.2).  
While our data does not explicitly prove the involvement of NFκB in PIAS1-induced UV 
hypersensitivity, the gene expression data does suggest that PIAS1 expression leads to an altered 
transcriptional state that sensitizes cells to UV irradiation. We showed that many of the genes 
whose expression is altered in PIAS1-expressing cells are transcriptionally controlled by NFκB, 
or specifically, by RelB.  The current model of PIAS1-mediated regulation presents only a 
repressive interaction between PIAS1 and NFκB. Interestingly, only a subset of κB promoters 
are subjected to regulation by PIAS1 (23). It is not currently understood what drives this gene-
selective regulation. Non-canonical κB promoters have been described (24) and a subset of these 
might be specific for PIAS1-dependent regulation. Further analysis of this will require chromatin 
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immunoprecipitation-sequencing (ChIP-Seq) assays using both anti-PIAS1 and anti-RelB 
antibodies.  
RelA is known to be induced by UV radiation. RelA translocates into the nucleus and 
binds to DNA in response to UV irradiation (25). A role for RelB in UV response has not been 
described, but RelB regulates transcription of anti-apoptotic factors and thus, has a role in cell 
survival (7). Substantial cross-talk occurs between RelA and RelB and each one can regulate the 
activity of the other (26, 27). It is possible that both RelA and RelB are induced in PIAS1-
expressing cells and that they regulate each other. Suppression of RelA-regulated genes (such as 
TRAF2, TRAF3) might increase nuclear translocation of RelB; RelB can then be regulated in the 
nucleus by Daxx and also directly by PIAS1. RelB has not been shown to SUMOylated, but 
there are potential SUMOylatable lysines on RelB that can be analyzed for PIAS1-directed 
SUMOylation. In this regard, generation of RelB mutants that cannot interact with PIAS1 will be 
valuable for further analysis role of PIAS1 in regulation of RelB. 
 Finally, since we see changes in the expression of both RelB regulated genes and genes 
that regulate RelB activation, PIAS1-mediated regulation of NFkB pathway will be complex 
with active negative and positive feedback loops. Discerning the sequence of events leading to 
the regulation of RelB activity will be essential for determining the mechanism of PIAS1 
induced UV-hypersensitivity. 
 
EXPERIMENTAL PROCEDURES 
RNA Extraction and Bcl2 family gene expression analysis: Total cellular RNA was extracted 
from sorted mCherry-expressing or PIAS1mCherry-expressing cells using the cell lysis buffer 
from Signosis Single Cell RT-PCR Assay kit (Signosis Inc., Sunnyvale CA) as described in the 
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manufacturer’s protocol. Expression of Bcl2 family genes was analyzed using the TaKaRa Inc. 
ApoPrimer Set (Bcl2 family) (Clontech Labs, Mountain View, CA) following manufacturer’s 
protocol. Expression of β-actin was used as a control for normalizing gene expression. Transcript 
amounts was analyzed by measuring the intensity of bands on agarose gel following 
electrophoresis using Image Station 4000R (Kodak). 
Apoptotic genes PCR Array: RT2 PCR Array that can screen for transcript levels of 84-
apoptosis related genes was obtained from SABiosciences/Qiagen. PIAS1mCherry- or mCherry-
expressing HeLa cells were sorted and total RNA extracted using Qiagen RNeasy kit. 1μg of 
RNA was used in a reverse transcription reaction to generate cDNA using the Qiagen RT2 First 
Strand kit. PCR Array was used as per manufacturer’s protocol using reagents specified by the 
manufacturer. Applied Biosystem’s Step One Plus Real-Time PCR machine was used for 
amplification. Expression data was analyzed using web-based analysis software from 
SABiosciences (sabiosciences.com/pcrarraydataanalysis.php). ΔΔCT based fold change 
calculation was used to identify genes with changes in gene expression. Genes that showed fold-
regulation (2ΔΔCT) value of 2 or higher in three independent arrays were considered for further 
analysis.  
Cross-linked Immunoprecipitation: HeLa cells were transfected with PIAS1wt or PIAS1 132C 
expression vectors at approximately 60-70% confluency (10cm culture dishes). 24 hours after 
transcfection, cells were washed twice with PBS, pH8.5 and incubated in 5mM DTBP (Dimethyl 
3,3´-dithiobispropionimidate•2 HCl; Thermo Fisher Scientific, Rockford, IL) in PBS, pH 8.5 for 
15 min at room temperature. Cells were washed twice in PBS and incubated in DTBP quenching 
buffer (100mM Tris HCl, pH 8.0, 150mM NaCl) for 10 min. Cells were washed with PBS, 
scraped off the dishes and pelleted. Cells were then lysed in RIPA buffer (50mM Tris, pH8.0, 
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150mM NaCl, 1% NP40, 0.5% Na.deoxycholate, 0.1% SDS) for 30 min at 4C, sonicated to 
disrupt DNA and then incubated with rabbit IgG, anti-PIAS1 antibody or anti-Daxx antibody for 
1 hour at 4C. Dynabeads coupled to Protein-A (Invitrogen, Carlsbad, CA) was added to the 
lysate and antibody solution and incubated overnight at 4C. Beads were washed four-times with 
a series of wash buffers (RIPA, RIPA+250mM NaCl, PBS-T, PBS-T+250mM NaCl, PBS) for 5 
min each at room temperature and the bound proteins were eluted by adding 1X SDS-PAGE 
buffer and heating at 95C for 10 min with vigorous vortexing every 5 min.  
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CHAPTER 5 
PIAS1-induced UV-hypersensitivity: current understanding and future 
perspectives 
 
UV radiation induces apoptosis in cells 
Apoptosis is an essential process for both the regular turnover of old and damaged cells as well 
as for regulated differentiation and development of multicellular organisms. Loss of regulated 
apoptosis leads to various degenerative diseases as well as tumorigenesis. Cells undergoing 
apoptosis round up and shrink; the chromatin condenses and degrades and nuclear envelope-
enclosed nuclear bodies are generated; cells fragment into apoptotic bodies, the 
phosphatidylserine, which is normally present in the inner leaflet of the plasma membrane, is 
exposed on the surface of apoptotic bodies and triggers engulfment by macrophages (1). 
Apoptosis progresses through both extrinsic and intrinsic pathway. Although the two pathways 
are biochemically distinct, there is a lot of crosstalk between them (2). The extrinsic pathway is 
initiated by binding of cell surface death receptors with their cognate ligands (3). Clustering of 
receptors and ligand binding leads to recruitment of cytoplasmic adaptor proteins, such as FADD 
(Fas activated death domain), that in turn recruits procaspase-8. Together, this large complex 
called the Death Inducing Signaling Complex (DISC) (4) leads to autocatalytic activation of pro-
caspase8. The intrinsic pathway is also called the mitochondrial pathway. Triggering of the 
intrinsic pathway leads to a loss of mitochondrial transmembrane potential, opening of the 
mitochondrial transition pore and release of certain pro-apoptotic proteins from the 
intermembrane space, including cytochrome-c.  Cytochrome-c release is regulated by the Bcl-2 
 
92 
 
family of proteins that include both pro- and anti-apoptotic proteins. Cytochrome-c binds Apaf-1 
(Apoptotic protease activating factor-1) which in turn recruits procaspase9 and leads to its 
proteolytic cleavage and autoactivation. Caspase8, caspase9 and caspase10 lead to the activation 
of the effector caspases such as caspase3, caspase6 and caspase7. The effector caspases in turn 
activate endonucleases that cause DNA fragmentation as well as proteases that degrade cytosolic 
and nuclear proteins (5). 
 UV radiation (UVR) can activate either the DNA repair pathway or apoptosis in cells. 
UVR is a short wavelength electromagnetic radiation that is somewhat arbitrarily divided into 
three components; UV-A (320-400 nm), UV-B (290-320 nm) and UV-C (200-290 nm). UV-B 
and UV-C cause lesions in DNA by forming cyclobutane pyrimidine dimers and (6-4) 
pyrimidine pyrimidone photoproducts. These lesions can be repaired by the Nucleotide 
Exchange Repair (NER) pathway. UVR can trigger both the extrinsic and intrinsic pathways of 
apoptosis. The intrinsic pathway is triggered by DNA damage, may be p53-dependent or -
independent depending on the cell type, and involve DNA-mismatch repair system (MMR) (1, 
6). UVR can also cause activation of Fas, TNF-R1 and TRAIL (TNF Receptor Apoptosis 
Inducing Ligand) receptors, and thus trigger the extrinsic pathway. UV is also known to induce 
the expression of the Fas ligand (FasL) (7). Although UVR triggers both the extrinsic and the 
intrinsic pathways of apoptosis, the two pathways act in an independent and additive manner. 
Inhibition of either the DNA damage induced pathway by expression of photolyase in cells, or 
the extrinsic pathway by blocking receptor clustering at low temperatures results in only a partial 
inhibition of apoptosis. However, DNA damage appears to be a more potent inducer of apoptosis 
(6, 8).  
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 UV-B and UV-C also modulate transcription activity in cells by activating a number of 
transcription factors including p53, AP-1 (c-fos and c-jun) and NFκB (9). Activation of p53 leads 
to induction of p21 and cell cycle arrest (10, 11). Transcription factors c-Jun and c-fos are 
activated by phosphorylation mediated by upstream kinases c-Jun N-terminal Kinase (JNK) and 
p38 mitogen activated protein kinases (MAPKs). JNK activation is associated with increased 
sensitivity of cells to UVR (12) and does not require damage to DNA (13). The canonical NFκB 
is also induced by UVR (13) in a DNA damage independent manner. UVR causes degradation of 
the inhibitory cytosolic protein IκBα and nuclear translocation and DNA binding by RelA (9). 
UV-C has been shown to induce RelA to act as a repressor of certain anti-apoptotic genes such 
as XIAP and Bcl-xl (14).  
 
PIAS1 plays an important role in UV-induced apoptosis 
In this dissertation, we showed that exogenous expression (Figure 2.1) of SUMO E3 ligase 
PIAS1 causes increased sensitivity of cells to UVR.  PIAS1 SUMO E3 ligase activity is essential 
for increased sensitivity to UV as a ligase-dead mutant of PIAS1 fails to elicit this response in 
HeLa cells (Figure 2.3). Using immunoblot, we compared the SUMOylation profile of the PIAS 
family by overexpressing them in cells. We observed several distinct SUMO-modified bands on 
expression of each of the PIASes in cells (Figure 2.2B). Also, each of the PIASes shows distinct 
nuclear localization and foci formation and colocalization with both SUMO-1 and SUMO-2/3 
(Figure 2.2A). We showed that the PIAS1 N-terminus SAP domain as well as the SIM domain is 
essential for its correct localization and substrate selection in cells (Figure 3.2). Thus, PIAS1-
induced hypersensitivity to UV may be mediated by distinct substrates SUMOylated by PIAS1 
expression in cells. To further understand the role of PIAS1 in UV-induced apoptosis, we 
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depleted PIAS1 from HeLa cells using siRNA (Figure 5.1A). Interestingly, depletion of PIAS1 
in HeLa cells using RNAi also caused increased apoptosis following UVR, although the kinetics 
of apoptosis induction is different. Increased apoptosis was seen 4 hours after UVR in cells 
exogenously expressing PIAS1 whereas in PIAS1-depleted cells, apoptosis occurred 8 hours 
after UVR. This difference in kinetics could reflect different pathways being targeted by PIAS1.  
As discussed earlier in this chapter, UVR initiates a DNA damage response, modulates 
transcriptional activity and activates apoptotic pathways in cells. We first tested some of the 
known DNA damage response pathway proteins that are known to be SUMOylated in cells. 
However, we did not observe distinct colocalization of XRCC1, BLM or RPA70 (15-17) with 
PIAS1 (Figure 5.1B). 
 
 
Figure 5.1(A) and (B): PIAS1 depletion sensitizes HeLa cells to UV irradiation. PIAS1 RNAi-treated HeLa cells 
show increased apoptosis after UV irradiation. HeLa cells were treated with PIAS1 siRNA or control siRNA for 48 
hours before treatment with 30J/m2 UV irradiation. Apoptotic cells were counted by Annexin V staining every four 
hours. PIAS1 siRNA-treated HeLa cells show an almost 40% increase in apoptotic cells 8 hours after UV irradiation 
compared with control siRNA-treated cells. The plotted values are an average of three independent experiments, and 
the error bars represent 1 SEM. PIAS1 RNAi reduces the amount of PIAS1 in HeLa cells to less than 10% of the 
control RNAi treatment. siRNA against PIAS1 was also obtained from Invitrogen (PIAS1 siRNA: 
PIAS1VHS41400). Cells were transfected with 200 pmol PIAS1 siRNA and UV irradiated 48 hours after 
transfection. The depletion efficiencies of the target proteins were estimated by immunoblotting followed by 
measuring the intensity of the bands with Image Station 4000R (Kodak).  (C) PIAS1 does not colocalize with 
BLM, XRCC1 or RPA70. PIAS1-mCherry expressing cells were irradiated with 30J/m2 of UV. The cells were 
fixed 4 hours after irradiation and immunostained with anti-BLM (Calbiochem), anti-XRCC1 (Santa Cruz 
Biotechnology) or anti-RPA70 (Abcam) antibodies, followed by Alexa dye-tagged secondary antibodies 
(Invitrogen) and Hoechst 33342 dye. None of the proteins tested showed colocalization with PIAS1. 
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Daxx acts as an effector of PIAS1-mediated UV-hypersensitivity 
We next aimed to identify the proteins that colocalize with PIAS1 at the PIAS1-SUMO foci as 
these could potentially interact with PIAS1-SUMOylated substrates and act as downstream 
effectors of PIAS1-induced UV hypersensitivity. We identified Daxx as an apoptotic protein that 
localizes significantly at PIAS1 SUMOylated foci but not with other PIASes (Figure 5.2). Daxx 
is an apoptotic pathway protein that functions as a transcriptional co-regulator for a number of 
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SUMOylated transcriptional factors (11). Daxx has been mainly shown to act as a co-repressor 
but can also act as a co-activator in some cases (18-20). Daxx itself is a known SUMO-modified 
protein (21), but we did not observe a stimulation of Daxx SUMOylation in PIAS1-expressing 
cells (Figure 3.4A). Thus, although Daxx is recruited to PIAS1-SUMOylated foci, it is not a 
substrate of SUMO in PIAS1-expressing cells. ). Furthermore, PIAS1 interaction with Daxx 
occurs even in the absence of UV (Figure 5.3). 
 
 
 
Figure 5.2: PIAS1, but not other PIASes, colocalize with Daxx. The PIAS1, PIAS2/Xα, PIAS3 and PIAS4/y C-
terminal mCherry fusion constructs were transfected into HeLa cells. The cells were immunostained with anti-Daxx 
and anti-SUMO-2/3 antibodies 24 hours after transfection. All PIASes disrupt normal Daxx foci in cells, but only 
PIAS1 shows significant colocalization with Daxx. 
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Figure 5.3: PIAS1 and Daxx colocalize in both mock- and UV-irradiated cells. PIAS1 recruits Daxx (indicated 
by arrows) to SUMOylated foci in both mock- and UV-irradiated cells. PIAS1 localization in the nuclei is not 
discernibly affected in mock- or UV-irradiated cells. 
 
 
 
Daxx has two SUMO interaction motifs, one at either terminus, that allow it to interact with 
SUMOylated transcription factors and also with SUMOylated PML (promyelocytic leukemia) 
bodies. Daxx interaction with PML is thought to preclude its transcriptional co-regulator activity. 
We observed a decrease in PML-Daxx interaction in cells expressing PIAS1, suggesting that 
Daxx was preferentially recruited to PIAS1-SUMOylated substrates. Of the two SIMs present in 
Daxx, we identified the C-terminal SIM to be essential for Daxx localization with PIAS1 and 
distinct nuclear foci formation (Figure 3.5B and 3.5C). Further, we showed that Daxx is required 
for PIAS1-induced UV-hypersensitivity as cells expressing PIAS1, but depleted in Daxx, 
showed significant reduction in apoptosis after UVR (Figure 2.5). In light of the data presented 
so far, we proposed a model wherein PIAS1 expression leads a cell to alter its transcription 
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profile to a stress-like state. Exogenously expressed PIAS1 mediates SUMOylation of certain 
substrates which may include transcription factors, co-regulators or chromatin modifiers that lead 
to recruitment of Daxx and changes in expression of genes that regulate apoptosis (Figure 5.4).  
 
 
 
Figure 5.4 PIAS1-directed SUMO-modified substrates recruit Daxx to mediate UV-hypersensitive apoptosis. 
Based on our data, we propose a model wherein the ectopic expression of PIAS1 promotes SUMOylation of specific 
substrates. One or more of these SUMOylated proteins recruit Daxx. The Daxx C-terminal SIM domain is necessary 
for this interaction. The Daxx-mediated corepression of certain transcription factors may then contribute to apoptosis 
after UV irradiation. 
 
PIAS1 potentially provides an alternative, p53-independent pathway for stress-induced 
apoptosis 
PIASes are known to regulate many transcription factors through SUMOylation and also by 
SUMO-independent mechanisms (22). SUMOylation often represses transcriptional activity by 
modifying the localization or DNA-binding ability of transcription factors. SUMOylation of 
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transcription factors, transcriptional co-regulators or chromatin modifiers also leads to formation 
of repressor complexes (22, 23). Tumor suppressor p53, which is an important modulator of 
cellular response to UV, is also SUMOylated by PIAS1 (24, 25). Expression of PIAS1 in both 
HeLa cells and in Hct116 cells causes increased cell death following UVR (Figure 5.4A and 
5.4B). Parental HeLa and Hct116 cells have similar response to UVR and show significant 
increase in apoptosis between 12 and 16 hours after UVR (Figure 5.4C). Hct116 cells have wild-
type levels of p53, whereas HeLa cells do not contain detectable levels of p53 [HeLa cells are 
cervical cancer cell lines that are positive for Human Papilloma Virus (HPV)-18; the E6 
oncoprotein from HPV-18 promotes Ubiquitin-mediated degradation of p53 (26, 27)]. Thus, 
PIAS1-mediated UV-sensitivity appears to be independent of the p53 pathway. As discussed 
earlier, p53 is an important effector of UV-induced apoptosis. Loss of p53 tumor suppressor 
activity is seen in most cancers. Thus, a p53-independent pathway to apoptosis in response to 
DNA damage appears to be an important alternative to ensure elimination of damaged, and 
potentially carcinogenic, cells. 
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Figure 5.5 Both HeLa and Hct116 cells show PIAS1 induced UV hypersensitivity (A) and (B) HeLa or Hct116 
cells were transfected with the PIASes, and apoptosis was calculated based on Annexin V staining four hours after 
mock or UV irradiation. (C) Apoptosis induced by UV irradiation in untransfected HeLa and Hct116 cells was 
determined by Annexin V staining every four hours over a 24-hour period after UV irradiation. 
 
PIAS1 potentially regulates NFκB transcriptional activity 
PIAS1 expression in HeLa cells changes gene expression of many apoptotic proteins. We 
showed that the expression of many of these proteins is controlled by the NFκB family of 
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transcription factors and some of these proteins themselves act as regulators of NFκB activity, 
specifically the non-canonical NFκB pathway that involves transcription factor RelB (Figure 
4.1B and Table 4.1). We also showed that both PIAS1 and Daxx are able to specifically interact 
with NFκB member RelB in PIAS1-expressing cells (Figure 4.2). Thus, NFκB appears to be a 
credible target of PIAS1 and Daxx in cells.  
The canonical NFκB pathway (RelA:p52 heterodimer) is known to be induced by UVR 
(9, 13). The non-canonical pathway (RelB:p50) has been studied extensively only in immune 
system development (28) and its role in stress response is not well analyzed. However, 
transcription of a number of anti-apoptotic genes has been shown to be controlled by RelB (29) 
(Table 4.1). The NFκB pathway is regulated by SUMOylation of upstream NFκB regulatory 
proteins such as IκBα (Inhibitor of NFκB) (30) and NEMO (NFκB Essential Modulator) (31). 
Both PIAS1 and PIAS3 have been shown to negatively regulate RelA transcriptional activity. 
PIAS1 inhibits DNA binding of RelA (32), whereas PIAS3 SUMOylates RelA only when it is 
bound to DNA and inhibits transcription presumably by preventing its interaction with co-
activators (33, 34). Transcription activity of both RelA and RelB are also repressed by Daxx. 
Daxx prevents CBP mediated acetylation and activation of RelA (35). And represses RelB by 
recruiting DNA methyl transferase 1 enzyme (DNMT1) to RelB promoters (29). It is not known 
if SUMOylation of the NFκB factors is required for recruitment of Daxx to either protein. Since 
we showed RelB to interact with PIAS1, it would be interesting to examine RelB SUMOylation 
in cells. We have identified four potential SUMOylation sites on RelB (K232, K256, K330 and 
K362). Of these, lysines 232 and 330 lie in the groove that binds DNA and thus SUMOylation 
on either of these two residues can potentially interfere with DNA binding; whereas 
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SUMOylation on lysines 256 and 362 can alter interactions with co-activators or co-repressors. 
We will test each of these sites for SUMOylation in vitro and in vivo.  
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Figure 5.6 The non-canonical NFκB pathway is potentially regulated by PIAS1 expression. (A) Stress stimulus 
induces translocation of RelB to the nucleus where it induces transcription of anti-apoptotic genes. (B) RelB 
translocates to the nucleus in the absence of stress stimulus but its transcription activity is repressed by PIAS1 and 
Daxx. (See text for detailed explanation). 
 
As described in chapter 4, RelB is held inactive in the cytoplasm by the p100 protein. 
TRAF2 and TRAF3 (Tumor Necrosis Factor Receptor Associated Factor) proteins form a 
Ubiquitin-ligase complex along with cIAP that continuously degrades NFκB-Inducing Kinase 
(NIK). Activating stress stimuli stabilizes NIK and leads to phosphorylation and degradation of 
the IκB-like domain of the p100 protein to generate the active p52 fragment. RelB and p52 
heterodimer translocates to the nucleus where it activates transcription of certain anti-apoptotic 
genes (Figure 5.6A) (36). Based on our data, we propose a model wherein PIAS1-expressing 
cells express lower amounts of TRAF2 and TRAF3 proteins (presumably by also modulating the 
canonical NFκB pathway) that leads to increased stabilization of NIK and hence increased 
translocation of RelB to the nucleus. This resembles a stressed-state, similar to that induced by a 
stress stimulus. However, PIAS1 also suppresses activation of genes downstream of RelB by 
recruitment of Daxx to RelB promoters (Figure 5.6B).  
 Thus, our data suggests that exogenous PIAS1 expression induces a stress-like state in 
cells by changing the expression of pro- and anti-apoptotic genes and regulating the NFκB 
pathway. Data from pias1-/- mice shows an increased activation of certain NFκB target genes 
(32). It would be interesting to identify apoptosis-related genes whose expressions are changed 
significantly in PIAS1-depleted cells and see if the same genes are targeted in both PIAS1-
overexpression and PIAS1-depletion models. PIAS1 has been shown to induce cell death in 
response to reactive oxygen species (ROS) via induction of JNK (37). PIAS1 also localizes to 
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double strand break foci generated by ionizing radiation (38). Thus, PIAS1 appears to be an 
important player in various stress response pathways. 
 
This dissertation emphasizes the essential role that PIAS1 plays in UV-stress response and has 
made significant contributions towards identification of some of the major interactors of PIAS1 
involved in cellular apoptotic response to UV. While both Daxx and NFκB are important for 
regulation of cell death following UVR, we do not yet have a coherent explanation for the 
complete pathway. While it is clear that Daxx acts on PIAS1-SUMOylated substrates, the 
substrates themselves remain to be identified and substantial efforts are being directed towards 
identification of global substrates of PIAS1 and also of other PIASes. NFκB itself seems to be 
regulated at multiple levels and the initial events that change gene regulation on PIAS1 
expression have not been determined. There is substantial cross-talk between the canonical and 
the non-canonical NFκB pathway and we envisage a similar interaction induced by PIAS1 
overexpression in cells. Future studies to further delineate the mechanism of PIAS1-induced UV-
hypersensitvity will benefit significantly from generation of inducible PIAS1 expressing cell 
lines. Further experiments to comprehend the involvement of the NFκB pathway will be required 
for a complete understanding of PIAS1-induced UV-hypersensitivity. 
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APPENDIX: Analysis of vertebrate PCNA SUMOylation 
 
INTRODUCTION 
Proliferating Cell Nuclear Antigen (PCNA) is the processivity factor for replicative DNA 
polymerases in eukaryotes. PCNA aids replicative polymerases delta and epsilon to remain on 
DNA for longer period during replication and thus allow replication of thousands of bases with a 
single replisome loading (1, 2). PCNA protein forms a homotrimer (3) and functions as a double 
homotrimer complex (4) that assembles around the DNA with the help of a clamp loader 
chaperone-like complex called Replication Factor C (RFC) (5). PCNA itself is devoid of any 
enzymatic activity but it functions as a platform for assembly of multi-protein complexes.  
PCNA has since been identified as a master player in a number of cellular pathways. 
PCNA interacts with Fen-1 endonuclease, which is required for processing of Okazaki 
fragments, during replication and enhances its activity (6). PCNA also binds to DNA ligase 1 at 
the ends of Okazaki fragments where DNA ligase 1 catalyzes phosphodiester bond formation 
between adjacent Okazaki fragments (7). In Xenopus egg extract, PCNA prevents reinitiation of 
replication by recruiting Cdt1-DDB Ubiquitin ligase complex to the DNA and thus ensuring 
degradation of replication licensing factor Cdt1 (8). In addition, PCNA participates in DNA 
repair by interacting with a host of proteins involved in mismatch repair, base excision repair and 
nucleotide excision repair; interacts with sister chromatid cohesion factors; chromatin 
remodelers; cell cycle regulators and apoptotic factors (9).   In yeast, PCNA also prevents 
recombination between sister chromatids by recruiting helicase Srs2 to the chromosomes (10, 
11). 
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PCNA has been shown to be both ubiquitinated and SUMOylated. PCNA modifications 
are very well studied in yeast. PCNA is ubiquitinated in response to DNA damage. 
Ubiquitination at lysine-164 (K164) recruits polymerases involved in translesion synthesis (TLS) 
to the site of DNA damage (12). TLS is a damage bypass pathway used during replication. 
During replication, when a replicative polymerase encounters damaged bases, the replication 
fork stalls. This triggers a damage response pathway culminating in mono-ubiquitination of 
PCNA on K164. This form of PCNA recruits low fidelity polymerases that are able to 
incorporate mismatched bases opposite to the damaged base site and thus continue with 
replication, albeit in an error-prone manner. PCNA can also be polyubiquitinated at the same 
lysine. The polyubiquitin chain is formed by Ubiquitin linking through K63 (not K48 on 
Ubiquitin, which is a signal for protein degradation). Polyubiquitin chain on PCNA recruits 
homologous recombination machinery that repairs DNA in an error-free manner (12). Lysine 
164 can also be SUMOylated and this modification leads to recruitment of a helicase Srs2 that 
prevents unnecessary recombination between sister chromatids (11). K164 SUMOylation also 
also controls recruitment of Eco1, a protein involved in sister chromatid cohesion during S-phase 
(13). Establishment of proper sister chromatid cohesion is important for faithful chromatid 
segregation in mitosis. In addition, PCNA is also SUMOylated on lysine 127, although the 
significance of this SUMOylation is not well-studied (12).  
PCNA is highly conserved from yeast to mammals; however, PCNA SUMOylation is not 
well-studied in vertebrates. Xenopus laevis PCNA is 62% similar to Saccharomyces cerevisae 
PCNA and has been shown to be modified by both SUMO and Ubiquitin on K164 during S-
phase. Xenopus PCNA is also diubiquitinated on DNA damage (14). However, K127 is not 
conserved between Xenopus and the yeast PCNA. PCNA SUMOylation and ubiquitination has 
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also been described in chicken DT40 cells (15), but only mono-ubiquitination on K164 has been 
described in response to DNA damage to mammalian cells. Human PCNA and Xenopus PCNA 
share 89% identity at the protein sequence level. Monoubiquitination of PCNA in mammalian 
cells is required for recruitment of DNA polymerase η (eta) to damaged DNA and translesion 
synthesis (16, 17). In addition, no homolog of yeast PCNA-SUMO interacting protein helicase 
Srs2 has been identified in higher eukaryotes. We sought to further elucidate the role of PCNA 
SUMOylation in Xenopus egg extract and identify SUMOylation of PCNA in mammalian cells. 
 
RESULTS 
PCNA is SUMOylated and ubiquitinated only during the S-phase in Xenopus egg extracts 
We first repeated the earlier observations that PCNA is SUMOylated and ubiquitinated in 
Xenopus egg extracts during normal S-phase. Xenopus egg extract is very well-suited to study 
proteins regulated in a cell cycle dependent manner. The egg extract is prepared by spinning eggs 
at high centrifugal forces that separates lipid and nuclear components from the crude soluble 
fraction (CSF) that represents the mitotic stage of cell cycle. When sperm DNA is added at this 
stage, mitotic chromatin is assembled. Interphase (S-phase) can be activated by addition of Ca+2 
and the extract can be forced to re-enter mitosis by addition of more crude soluble fraction (CSF) 
to the interphase extract (Figure A1a).  
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Figure A1: PCNA is modified during S-phase in Xenopus egg extract. (a) Schematic representation showing 
Xenopus egg extract cycling through mitosis and interphase. (b) PCNA is SUMOylated and ubiquitinated during S-
phase, but not during mitosis on un-replicated or replicated chromosomes. Chromosomes were isolated from the 
respective stage of egg extract and chromosomal proteins immunoblotted with anti-PCNA antibody. (c) PCNA 
SUMOylation and ubiquitination first increases and then decreases as the chromosome replicates during S-phase. 
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Majority of chromosomal SUMOylation takes place during mitotic stage, but a small number of 
SUMOylated proteins can be identified during S-phase as well (Figure A1a). We observed 
slower mobility PCNA bands associated with the chromosome only during the interphase or the 
S-phase of egg extract (Figure A1b). Of the two slower mobility PCNA bands, the SUMOylated 
PCNA can be identified by disappearance of one of the bands when the extract is incubated with 
a dominant negative E2 enzyme (C93S) (18, 19). PCNA ubiquitination and SUMOylation cannot 
be observed during mitosis or when replicated chromosomes are induced to re-enter mitosis 
(Figure A1b). Amount of PCNA associated with chromosomes is also greatest during the S-
phase. Figure A1c (courtesy, Dr. Lin Cong) shows PCNA ubiquitination and SUMOylation 
increase steadily through the S-phase and then decreases as the chromosomes are fully 
replicated. Addition of dominant negative Ubc9 does not interfere with progression through S-
phase, thus, PCNA SUMOylation does not appear to be critical for replication of chromosomes. 
 
PCNA is modified by SUMO-2/3 in Xenopus egg extracts 
Leach and Michael (14) showed that PCNA is modified by SUMO-1 at a higher efficiency than 
SUMO-2 in Xenopus egg extract. However, they added excess recombinant GST-tagged SUMO 
to the extract to arrive at this conclusion. Endogenous situation may not necessarily reflect a 
preference for SUMO-1 over SUMO-2. In order to identify the SUMO isoforms that modifies 
PCNA in the egg extract, we performed PCNA IP from interphase chromosomes under 
denaturing conditions that prevents deSUMOylation by SUMO proteases. We identified only 
SUMO-2 modified form of PCNA associated with chromosome in the egg extracts (Figure A2, 
courtesy of Dr Lin Cong). Thus, under native conditions, PCNA is modified by SUMO-2. 
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PCNA SUMOylation in vitro requires SUMO E3 ligase 
In order to further analyze PCNA SUMOylation in vitro, we cloned and purified recombinant 
Xenopus PCNA protein. We used this protein in an in vitro SUMOylation assay with varying 
concentrations of E2 SUMO conjugating enzyme (Ubc9) and E3 SUMO ligase (PIASy). We 
compared in vitro PCNA SUMOylation to Parp1 SUMOylation, a SUMO substrate that has been 
well characterized in the lab earlier (20). In vitro PCNA SUMOylation is very inefficient 
compared to Parp1 SUMOylation (compare Figures A3a and A3b). Also, while Parp1 can be 
SUMOylated by E2 alone, PCNA SUMOylation requires the presence of an E3 ligase. In 
addition, we saw two PCNA-SUMO bands (Figure A3a), suggesting in vitro, Xenopus PCNA 
can be modified at two sites. 
Figure A2: PCNA is modified by SUMO-2 in Xenopus 
egg extract. PCNA bound to interphase chromosome was 
immunoprecipated under denaturing conditions and 
immunoblotted with anti-PCNA, anti-SUMO-1 and anti-
SUMO-2/3 antibodies. A 55 kD band corresponding to the 
SUMO-modified form of PCNA was identified only in the 
SUMO-2 immunoblot (indicated by red arrows). Figure 
courtesy, Dr Lin Cong. 
 
114 
 
 
Figure A3: In vitro PCNA SUMOylation is E3-dependent. (a) In vitro SUMOylation of Xenopus is dependent on 
the presence of E3 SUMO ligase enzyme. Xenopus PCNA is modified at two sites in vitro. (b) In vitro 
SUMOylation of Parp1 as a control. Parp1 can be SUMOylated even in the absence of an E3 enzyme. 
 
 
PCNA can be modified at lysines 164 and 254 in vitro 
PCNA SUMOylation at K164 is already described. K164 is a non-consensus SUMOylation site. 
We studied the PCNA structure (3) to identify surface-exposed lysine residues and used the 
SUMOsp 2.0 online software (21) to identify potential SUMOylation sites. We identified lysine 
254 as a second potential SUMOylation site on Xenopus PCNA. Lysine 254 is part of a 
consensus SUMO motif ΨKXE (Ψ=hydrophobic amino acid, K=lysine, X=any amino acid, 
E=glutamate). We created lysine to arginine mutants of each of these lysines and also a double 
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mutant (DM = K164, 254R) on PCNA and verified K164 and K254 to be the sites of SUMO 
modification in vitro. Also, our data suggests that K164 SUMOylation efficiency can be slightly 
improved by increasing the concentration of E2, whereas, K254 SUMOylation is independent of 
the E2 concentration. We also, at times, saw weak SUMOylation on additional sites on PCNA in 
the double mutant (Figures A4a and A4b). This is not unusual, as in vitro, additional lysines can 
be modified when the primary SUMOylation sites have been mutated, although such 
modifications may be restricted in vivo. 
 
 
Figure A4(a) and (b): Xenopus PCNA can be modified on lysine-164 and lysine-254 in vitro. Both lysine 164 
and lysine 254 in Xenopus PCNA were identified as SUMO-modification sites in vitro. In vitro reaction contained 
60nM E3 ligase in (a) and 30nM E2 in (b). 
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Both the SUMOylation sites in PCNA show a preference for SUMO-2 over SUMO-1 in vivo 
In order to identify any SUMO isoforms preference for both lysines 164 and 254, we used equal 
concentrations of SUMO-1 and SUMO-2 in in vitro SUMOylation reactions (Figure A5). Both 
the lysines were observed to be SUMOylated at a higher efficiency by SUMO-2. 
 
Figure A5: PCNA is modified preferentially by SUMO-2 in vitro PCNA SUMOylation was carried out in the 
presence of equal concentration of either SUMO-1 or SUMO-2. SUMO-2 modification of PCNA was found to be 
more efficient. 
 
PCNA is not modified at K254 in Xenopus egg extract 
Since PCNA ubiquitination and SUMOylation has been described only at K164 in Xenopus egg 
extract, we sought to identify secondary SUMOylation sites on PCNA in the egg extract. We 
added recombinant his-tagged PCNA wild-type and PCNA mutants to the egg extract and 
incubated the extracts either in the presence or absence of aphidicolin. Aphidicolin is a reversible 
inhibitor of DNA polymerase and thus inhibits cells progression through the S-phase. Addition 
of aphidocolin prolongs retention of replication machinery on the chromosome. We then pulled 
down his-tagged PCNA assembled on purified interphase chromosomes. Wild-type as well as the 
mutant PCNAs were able to bind to the chromosome. Addition of excess wild-type or mutant 
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PCNA did not interfere with entry or progression of the extract through interphase.  Aphidicolin 
addition prevented replication of chromosomal DNA but not loading of PCNA on the 
chromosomes. We could observe both the ubiquitinated and the SUMOylated forms of PCNAwt 
as well as PCNA K254R in either aphidicolin-treated or untreated samples. In addition, we could 
identify a di-ubiquitinated form of PCNA (indicated by asterisk in the figure) in the aphidicolin-
treated samples in PCNAwt and PCNA K254R mutant, as reported earlier (14). PCNA K164R 
and PCNA DM did not show either ubiquitination or SUMOylation under conditions of normal 
DNA replication or when replication was inhibited using aphidicolin. Thus, our data suggests 
that PCNA K254 may not be a SUMOylation site in egg extracts.  
 
 
Figure A6: PCNA lysine 254 is not a site of modification in Xenopus egg extracts. Interphase was induced in 
Xenopus egg extract by addition of Ca+2. PCNAwt or PCNA mutants were added to the extract in the presence or 
absence of replication inhibitor Aphidicolin. Lysine 254 was not shown to be SUMOylated or ubiquitinated under 
the conditions tested. 
 
DISCUSSION 
We showed that Xenopus PCNA can be SUMOylated at two sites (lysines 164 and 254) in vitro 
but could not identify any conditions wherein lysine 254 is modified in the egg extracts. In 2010, 
Xu et al. (22) showed that in mammalian PCNA from HEK293T cells is modified by Ubiquitin. 
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They also showed that ubiquitination on K254, but not K164, increased significantly when 
HEK293T cells were treated with mitotic spindle inhibitor drug colchicine. Although 
ubiquitination of mammalian PCNA at K164 has been described before, SUMOylation of PCNA 
in mammalian cells was not shown until recently. We tried to observe PCNA SUMOylation in 
HeLa, Hct116 as well as U2OS cell lines but were not successful. We also used a U2OS line 
overexpressing SUMO-2, but could not detect any slow-migrating PCNA bands from cell 
extracts. More recently, Gali et al. (23) were able to detect SUMO modified forms of PCNA 
when they transiently overexpressed PCNA, Ubc9 and one of the SUMO isoforms in HEK293T 
cells. They also identified K254 as a secondary SUMO modification site in vitro. Further, they 
showed that PCNA SUMOylation protects against double-strand break formation at stalled 
replication forks.  
 Any future work in the field of PCNA SUMOylation in mammalian cells will be aimed at 
identifying specific interactors of SUMOylated PCNA. Since PCNA SUMOylation can be 
detected in mammalian cells only when the substrate as well as Ubc9 and SUMO are 
overexpressed, identifying specific conditions under which PCNA SUMOylation occurs in cells 
will be important for further analysis. Also, since PCNA SUMOylation is easily detected in B-
cell derived DT40 chicken cell lines, PCNA SUMOylation in mammals may similarly occur 
more efficiently in B-cells that undergo DNA recombination at high rates. Thus, it maybe 
advantageous to study PCNA SUMOylation in mammalian B-cell lines. 
 
EXPERIMENTAL PROCEDURES 
Cloning and recombinant protein purification: Xenopus PCNA was cloned into pET28b 
vector. PCNA SUMOylation site mutants were generated by site-directed mutagenesis using 
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Stratagene Quikchange mutagenesis kit. Proteins were expressed in E.coli BL21DE3 strain and 
purified using Ni-NTA beads followed by further purification on a Q-sepharose column. 
In vitro SUMOylation assay: In vitro SUMOylation was performed as described in (20). 
Briefly, 15nM E1, 5uM SUMO-1 or SUMO-2, 2.5mM ATP and 500nM PCNA was incubated in 
the reaction buffer (20mM Tris, 100mM NaCl, 10mM MgCl2, 0.05% Tween-20 and 0.5mM 
DTT) together with the indicated concentrations of E2 (Ubc9) and E3 (PIASy) enzymes. 
Reactions were incubated at 25˚C for 1 hour.  
Xenopus egg extract assay: Xenopus egg extract was prepared as described in (24). CSF 
extracts were induced to enter interphase by addition of 0.6mM CaCl2. Demembranated sperm 
chromatin were added to the interphase extract and incubated for 1 hour. Chromosome was 
isolated as described (24). 
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